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RESUMO 
A tuberculose, uma doença devastadora causada por bactérias do complexo Mycobacterium tuberculosis 
(MTBC), mantém-se vastamente fora de controlo. Embora a imunidade mediada por células T positivas 
para cluster de diferenciação 4 (T CD4+) seja crítica para o controlo da infeção, não existe um 
conhecimento profundo sobre as características das respostas protetoras mediadas por células T bem 
como dos fatores que têm impacto no seu estabelecimento. Neste contexto, a diversidade genética do 
MTBC tem sido subestimada, visto que a maioria dos antigénios conhecidos de M. tuberculosis são 
hiperconservados. A existência de epítopos de células T variáveis foi investigada através da análise da 
diversidade, evolução e imunogenicidade de uma ilha genómica expressa in vivo (iVEGI) em 270 genomas 
do MTBC. A iVEGI apresentou um nível de diversidade nucleotídica acima da média do genoma, devido 
à presença de 21 genes altamente diversos. A análise computacional de evolução molecular previu 11 
codões de nove genes como estando sob seleção diversificante. De particular interesse foram três 
substituições nos genes accD2, Rv0987 e Rv0988, que alteraram significativamente o número de 
péptidos codificados com elevada afinidade de ligação prevista para diferentes moléculas de antigénio 
leucocitário humano (HLA) de classe II. Ensaios in vitro realizados com o HLA DRB1*01:01 corroboraram 
a existência de péptidos com elevada afinidade de ligação e revelaram diferenças de mais de 58% na 
afinidade de ligação entre péptidos wild-type e mutante que sobrepõem AccD2 R233L e Rv0987 V169L. 
Notavelmente, o péptido AccD2228-241 demonstrou níveis de afinidade e estabilidade tão elevados como 
o controlo positivo ESAT-63-17, sendo assim um forte candidato para um epítopo de célula T CD4+ restrito 
a uma linhagem de M. tuberculosis. Durante a longa coevolução entre M. tuberculosis e populações 
humanas, a diversidade genética em epítopos específicos de células T pode ter sido selecionada de modo 
a induzir respostas imunes vantajosas para o agente patogénico. Revelar a trajetória evolutiva de M. 
tuberculosis em resposta à pressão imunológica pode oferecer ferramentas sem precedentes para 
explorar os seus alvos moleculares em favor do hospedeiro, nomeadamente para o desenvolvimento de 
vacinas mais eficientes. 
 
Palavras-Chave: Tuberculose; Mycobacterium tuberculosis; seleção diversificante; epítopo de células 
T, antigénio leucocitário humano          
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ABSTRACT 
Tuberculosis, a devastating disease caused by bacteria from the Mycobacterium tuberculosis complex 
(MTBC), remains vastly uncontrolled. Although cluster of differentiation 4 positive (CD4+) T cell-mediated 
immunity is critical for infection control, a deep knowledge on the characteristics of the protective T cell 
responses and on the factors impacting their establishment is lacking. In this context, the MTBC genetic 
diversity has been underappreciated, as most of the known M. tuberculosis antigens are hyperconserved. 
The existence of varying T cell epitopes was investigated by analysing the diversity, evolution and 
immunogenicity of an in vivo-expressed genomic island across 270 MTBC genomes. The in vivo-expressed 
genomic island displayed a level of nucleotide diversity above the whole-genome average due to the 
presence of 21 highly diverse genes. Computational molecular evolution analysis predicted 11 codons 
from nine genes to be under diversifying selection. Of particular interest were three substitutions in the 
genes accD2, Rv0987 and Rv0988, which significantly altered the number of encoded peptides with 
predicted high binding affinity to class II human leukocyte antigen (HLA) molecules. In vitro assays 
performed with HLA DRB1*01:01 corroborated the existence of high binding affinity peptides and 
revealed differences of more than 58% in the binding affinity between wild-type and variant peptides 
overlapping AccD2 R233L and Rv0987 V169L. Notably, the AccD2228-241 peptide showed affinity and 
stability levels as high as the positive control ESAT-63-17, thus being a strong candidate for an M. 
tuberculosis lineage-restricted CD4+ T cell epitope. During the long co-evolution of M. tuberculosis and 
human populations, genetic diversity in specific T cell epitopes might have been selected to induce 
immune responses advantageous for the pathogen. Unveiling the evolutionary path of M. tuberculosis in 
response to immune pressure might offer unprecedented tools to exploit its molecular targets in favour 
of the host, namely for the development of more efficient vaccines.  
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INTRODUCTION 
Tuberculosis: a major human health problem 
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis. Human 
TB affects primarily the lungs, where it leads to progressive tissue necrosis and cavity formation (Figure 
1A). Without treatment, patients get increasingly debilitated with fever, weight loss and ultimately 
respiratory failure [1,2]. In less common cases, the pathogen can disseminate and induce pathology in 
other parts of the body, such as the central nervous system, bones and the gastrointestinal tract [3]. Only 
pulmonary TB can lead to aerosol transmission of the tubercle bacilli to other individuals [4]. The single 
preventive strategy available is the Bacille-Calmette-Guérin vaccine (BCG), first administered in 1921. 
Unfortunately, this vaccine is only efficient in protecting children against disseminated TB and its efficacy 
against pulmonary TB in adults is highly variable [5,6]. It is estimated that at least one third of the world’s 
population had already inhaled airborne droplets containing M. tuberculosis [7]. Most people are able to 
control bacterial growth and remain asymptomatic (latent TB). Nevertheless, 5-10% will eventually 
manifest the active form of the disease [1,2]. This percentage is even higher in immunocompromised 
patients, such as the ones infected with the human immunodeficiency virus (HIV). According to the World 
Health Organization (WHO), nine million people developed TB in 2013, resulting in a tragic amount of 
1.5 million deaths (0.4 million due to HIV-associated TB) (Figure 1B) [7]. In fact, TB is only seconded by 
the acquired immune deficiency syndrome (AIDS) in terms of human casualties due to an infectious 
disease worldwide. Furthermore, TB also poses a high global economic burden, with eight billion dollars 
spent each year in diagnostic and treatment [7]. Once a person is diagnosed with TB, typical treatment 
relies on the administration of four antibiotics (isoniazid, rifampicin, ethambutol and pyrazinamide) over 
six months. Although this regime is highly effective among new cases (85% success), current global death 
rate decline is a modest 1-2% (Figure 1B) [7]. In addition to this, the emergence of drug-resistant strains 
threatens the use of antibiotics in the future [7]. Therefore, new therapeutic strategies are urgently needed 
to tackle this disease. 
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The origin of human TB 
TB has been a cause of human death since the antiquity. The earliest written evidence of the disease was 
found in 4700-year old Chinese medical manuscripts [9]. Paleopathological lesions characteristic of TB 
were also detected in human remains dated from various historical periods of the human civilization and 
found in several locations around the globe. These include ancient Syria (8200-7600 BC) [10], Israel 
(7250-6160 BC) [11], Germany (5400-4800 BC) [12], Egypt (2050-1650 BC) [13], United Kingdom 
(400–230 BC) [14] and more recently Hungary (1731–1838 AD) [15]. It is estimated that 25% of the 
Egyptians mummified after 3400 BC suffered from TB [16]. A similar scenario was also true for all adults 
that died in Europe during the Industrial Revolution [17].  
The etiologic agent of human TB remained unknown until the isolation of M. tuberculosis in 1882, by 
Robert Koch [18]. In 1896, taxonomists Lehmann and Neumann included M. tuberculosis in the 
Mycobacterium genus, alongside with another important human pathogen, Mycobacterium leprae [19]. 
Two years later, Theobald Smith isolated a similar organism (posteriorly named Mycobacterium bovis) 
from cattle with TB-like clinical presentation [20]. Since then, other TB-causing bacteria have been 
recovered from wild and domestic mammals, such as goats and sheep (Mycobacterium caprae) [21], 
seals (Mycobacterium pinnipedii) [22] and rodents (Mycobacterium microti) [23]. Nowadays, it is known 
that these bacteria share a high level of similarity at the nucleotide level and together constitute the 
Mycobacterium tuberculosis complex (MTBC) [24,25]. Contrarily to the majority of the mycobacteria, 
members of the MTBC are obligate pathogens with no known environmental reservoir [26,27]. In addition, 
MTBC bacteria are found in a limited number of different host species [26,27]. Since mycobacteria were 
(A) (B)
Figure 1. Pathology and death rate of human TB. (A) Gross appearance of TB dissemination in the lungs of a 35-year 
old male individual infected with HIV [8]. (B) Estimated number of TB deaths in millions per year, 1990–2013 [7]. Reproduced 
with permission from WHO, ID 182946. 
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already widely dispersed before the existence of animal kingdom, some of them may have evolved to 
colonize specific hosts during the early expansion of animal life on Earth [26]. Owing to its broader host 
spectrum [28], M. bovis was believed to be the most recent common ancestral (MRCA) of the MTBC. In 
that sense, the bacterium was thought to have spread to humans due to close contact with infected cattle 
[26]. However, analysis of its genome revealed no new genes comparatively to M. tuberculosis [29]. 
Instead, the genomes of M. bovis and other animal-adapted MTBC species were found to be smaller due 
to the accumulation of large deletions [24]. Since horizontal gene transfer is thought to be scarce across 
MTBC [30,31], these losses of genetic material must have occurred once and could not have been 
reverted over time. Thus, it was proposed that human and animal-adapted MTBC members were two 
distinct clades and that the ancestral of the complex would be more similar to M. tuberculosis [24]. In 
support of this notion, skeletal evidence indicated that human TB was present before the early stages of 
animal domestication [10]. Moreover, although animal-adapted MTBC bacteria can occasionally infect 
humans [32,33], the ability to transmit TB seems to be restricted to M. tuberculosis [26,34]. Significant 
advances in finding the MRCA of the MTBC were made in 2013, with the inclusion of Mycobacterium 
canettii (an occasional human TB-causing bacterium [35]), as a member of the complex. The genome of 
M. canettii was found to be larger than any other MTBC bacterium, while sharing more than 95% 
nucleotide sequence identity [36]. It was also reported that M. canettii displays ongoing horizontal gene 
transfer and recombination between strains [36,37], similarly to other environmental mycobacteria 
[38,39]. Together, all these characteristics placed M. canettii in the early branches of the MTBC evolution 
[36]. The mechanisms underlying the transition of an M. canettii-like ancestral to M. tuberculosis are not 
fully clarified [36,40] and will not be discussed in this thesis. In the next section, the focus will be on the 
population structure of MTBC and its impact on the human population. 
MTBC population structure  
In clinical settings, detection and classification of M. tuberculosis isolates is routinely performed through 
polymerase chain reaction (PCR) amplification of certain repetitive and polymorphic genomic regions of 
the bacterium [41]. The occurrence pattern of these deoxyribonucleic acid (DNA) stretches is 
characteristic of each strain and can be interrogated by two methods, spoligotyping [42] and 
mycobacterial interspersed repetitive units-variable number of tandem repeats (MIRU-VNTR) [43]. Over 
the years, the amount of data generated by these techniques lead to the creation of online databases, 
such as SITVITWEB [44]. Further analysis of the genotyping patterns available at SITVITWEB [44] and 
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others [45] revealed the existence of distinct groups of strains with variable predominance throughout the 
world. In other words, each considered geographical region seemed to have a prevailing genotype 
[44,45]. Other studies harnessing single and large sequence polymorphism (SNP and LSP) data also 
reached the same conclusions [46–49]. Although PCR-based typing is useful for epidemiological studies 
[41], it only assess the diversity within small portions of the genome. Alternatively, whole-genome 
sequencing has a much higher discriminatory power and can be used to measure the evolutionary 
relationships and distances between different strains [50]. A robust phylogenetic tree of the M. 
tuberculosis population (Figure 2) was constructed in 2013 by Iñaki Comas and colleagues [51]. To 
achieve that, the authors took advantage of 216 whole-genome sequences of clinical isolates from several 
regions of the globe. The study highlighted that the global M. tuberculosis diversity was distributed by 
seven main phylogenetic lineages, each one with a strong association for certain world regions. Lineage 
1 (also designated as Indo-Oceanic lineage) predominates in East Africa and South-East Asian countries 
(such as India, Philippines and Vietnam); lineage 2 is highly dispersed through Eastern Asia (e.g. China 
and Mongolia); lineage 3 is frequently found in Central Asia (e.g. India, Pakistan and Bangladesh) and to 
a lesser extent in East Africa; lineage 4 (Euro-American lineage) encompasses Europe, America, Africa 
and Middle-East; lineages 5 and 6 (also known as Mycobacterium africanum) are narrowly restricted to 
West Africa (e.g. Guinea-Bissau) and finally, lineage 7 was only found till date in Ethiopia [52]. It was also 
verified that the M. tuberculosis phylogeny was similar to a human phylogeny based on representative 
mitochondrial groups [51]. This suggested that the M. tuberculosis lineages could have followed the major 
human migrations out of the African continent, the cradle of mankind [49,51,53–55]. Lineages 1, 5 and 
6 were the first to diverge from a 70 000 year-old M. canetti-like progenitor and were designated as 
‘ancient’ MTBC lineages. In contrast, lineages 2, 3 and 4 (which shared a characteristic large genomic 
deletion [24]) were classified as ‘modern’ MTBC strains [51]. Additionally, animal-adapted MTBC strains 
were confirmed to share a common ancestral with M. tuberculosis, as aforementioned [24]. 
 5 
 
 
Genetic diversity among host and pathogen populations in TB 
TB is a heterogeneous disease with several outcomes and clinical manifestations upon exposure to its 
causative agent [1,2]. Much of this heterogeneity was linked with social and environmental factors in the 
past [56]. However, accumulating evidence has been showing that there is an intrinsic role of biological 
factors related with the bacterium, the host and the host-pathogen interaction.  
On the bacterium’s side, it was reported that the diversity among MTBC lineages and sub-lineages has 
clinical relevance, namely on disease onset, severity and transmission. For instance, a delay in seeking 
medical care was detected by Yimer et al. (2015) in Ethiopians infected with lineage 7 strains [57]. 
Parwati et al. (2010) associated lineage 2 with treatment failure [58] and Stavrum et al. (2014) related 
lineage 4 with more debilitating symptoms (such as weight loss) in Tanzanian individuals [59]. Albanna 
et al. (2011) found lineage 3 to be less transmissible than lineages 1, 2 and 4 across Montreal, Canada 
[60], whereas an increasing frequency of lineage 2 was described in South Africa by Cowley et al. (2008) 
[61]. At a sub-lineage level, Kato-Maeda et al. (2010) identified a highly transmissible sub-lineage of 
lineage 2 in San Francisco [62] and Gehre et al. (2013) registered striking differences in transmissibility 
Figure 2. Phylogeny of the MTBC based on whole-genomes of 216 M. tuberculosis and 3 animal-adapted 
strains. Major MTBC lineages are depicted by different colors. Scale bar indicates substitutions per site. Extracted from [51]. 
Reproduced with permission from Nature Publishing Group, license number 3717280653767. 
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among sub-lineages of lineage 5 in Benin and Nigeria [63]. Distinct lineage 2 strains were also found to 
impact the interaction with host innate immune system, either by preferentially activating the pattern 
recognition receptor (PRR) Toll-like receptor (TLR) 2 or TLR4 [64]. MTBC lineages are also not similar in 
epidemiological terms, with the ‘modern’ MTBC lineages 2 and 4 being the most widespread [44]. These 
have been correlated with a low induction of pro-inflammatory molecules in vitro [65,66] and a higher 
capacity to replicate in vivo when compared to ‘ancient’ MTBC strains [67]. Although the aforementioned 
studies emphasize the influence of pathogen diversity in TB, some controversial data can be found in the 
literature. For example, Marais et al. (2009) found the transmissibility not to be significantly associated 
with the M. tuberculosis genotype in South Africa [68] and Krishnan et al. (2011) also reported no 
significant alterations between lineage 1 and lineage 2 strains regarding the in vitro inflammatory profile 
[69]. These apparent contradictions in studies performed in different geographic areas might be related 
with the heterogeneity in human populations and its impact in TB. Clinical surveys revealed that a 
substantial part (30-50%) of household contacts with the disease did not result in measurable infection 
[70,71], thus suggesting that some people might be intrinsically less susceptible to TB. Indeed, the SNP 
rs2057178 on chromosome 11p13 was related with protection against TB in Gambia, Indonesia and 
Russia by a genome-wide association study (GWAS) [72]. Additionally, genetic mutations were found to 
cause Mendelian susceptibility to mycobacterial diseases (MSMD) [73,74], which is a primary 
immunodeficiency that leads to complications even with typically non-pathogenic mycobacteria  [75]. In 
addition, susceptibility and immune response to TB were also described to vary according to ethnicity 
[76,77]. Many other studies identified human genetic variants thought to influence the risk of developing 
TB (reviewed in [78] and [79]). Nevertheless, the results have been considered inconsistent and difficult 
to reproduce. Regarding these studies, the lack of incorporation of the nucleotide diversity and population 
structure of both the host and M. tuberculosis was appointed as one of the most prominent weaknesses 
[80]. 
Influence of the host-pathogen genetic diversity on TB 
Accumulating evidence has been showing that epidemiological and clinical aspects of TB are significantly 
shaped by the interaction between human and MTBC populations.  
At the epidemiological level, Gagneux et al. (2006) and Reed et al. (2009) demonstrated that the 
transmission dynamics of TB in highly urbanized settings (i.e. San Francisco [48] and Montreal [81]) 
were not random. Instead, MTBC lineages frequently found in established ethnic communities (namely 
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Chinese, Filipino and Vietnamese) were the ones that predominated in the corresponding countries of 
origin (Figure 3) [48,81]. Interestingly, Hirsh et al. (2004) had previously referred that the host’s ethnic 
origin could predict the MTBC lineage of the infecting strain [46].  
  
  
  
  
  
  
  
  
  
  
  
At the clinical level, de Jong et al. (2008) observed that lineages 2 and 4 had a higher rate of progression 
to active TB comparatively to lineage 6 in Gambia [83] and a multivariate analysis performed by Caws et 
al. (2008) showed that lineage 2 strains were more commonly found in Vietnamese patients with a 
particular polymorphism on the TLR2-encoding gene [84]. In Ghana (West Africa), Herb et al. (2008) 
reported a statistically significant association between a polymorphism (G254K) on the Arachidonate 5-
Lipoxygenase (ALOX5) gene and increased predisposition to develop TB due to lineage 6 [85]; Intemann 
et al. (2009) linked a nucleotide variant upstream of the Immunity-related GTPase M (IRGM) coding region 
with protection from TB caused by lineage 4 (and not by other MTBC lineages) [86]; and Thye et al. 
(2011) found that the LYQC haplotype of the Mannose-binding lectin 2 (MBL2) gene conferred an 
exclusive protective effect against lineages 5 and 6 [86]. Interestingly, the MBL2 LYQC haplotype is rarely 
found outside of sub-Saharan Africa (which encompasses West Africa region), suggesting that it could 
have had increased its frequency over time owing to its protection to endemic MTBC lineages. [87]. On 
the other hand, the exonic variant G254K of ALOX5 is highly frequent in Africa relative to other world 
regions [85], indicating that lineage 6 strains (abundant in West Africa) might have a selective advantage 
in hosts harbouring  the referred polymorphism.  
Figure 3. Transmission dynamics of TB in San Francisco, United States of America (2001-2009). The number 
of secondary TB cases is plotted as a function of the number of index cases (secondary case rate ratio) Pink, lineage 1 or 
Indo-Oceanic lineage; blue, lineage 2 or East Asian lineage and red, lineage 4 or Euro-American lineage. Adapted from [82]. 
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Overall, described findings indicated that MTBC lineages tend to be more successful (i.e. more adapted) 
upon infection of humans that share the same ancestral geographic region (sympatric) than with hosts 
of foreign ascendency (allopatric) [48,81,82,88].. Furthermore, genetic variants associated with host-
pathogen adaptation in TB might have arisen due to natural selection, rather than by chance (i.e. genetic 
drift) [89]. Consequently, the detection of molecular signatures of adaptation could reveal the basis 
underlying the success of M. tuberculosis and reveal potential targets for therapy design. 
Detection of diversifying selection 
Diversifying selection (also referred as positive selection [90]), is the directional action of natural selection 
to increase the prevalence of beneficial genetic variants over time (Figure 4) [91]. More importantly, 
diversifying selection is thought to be the main mechanism of adaptation in disease contexts [92]. 
Classical examples are the high frequency of sickle-cell anaemia (caused by a mutation in Hemoglobin-B 
gene) in malaria endemic regions [93] and the development of drug-resistance during treatment in HIV 
[94].  
The detection of diversifying selection is not easy if the selective pressure and its targets are not known. 
To try to mitigate these issues, numerous computational methods were developed to detect selection in 
genomic sequences by taking advantage of its increasing availability. Briefly, the methods can be divided 
in two types: the ones based on population genetics data and comparative genomics [91]. The population 
genetics-based methods apply statistical models in order to distinguish if variation among a representative 
sample of the population was randomly generated or fixed by selection. Typical evaluated datasets include 
linkage disequilibrium [96] or allelic frequency [97], for instance. Despite its popularity in human genetics, 
these methodologies are highly dependent on assumptions about the population demography, such as 
population size, that are not easily estimated in pathogen populations [91,98]. Furthermore,  the 
resolution provided is rarely to the codon level [98,99]. In contrast, comparative genomics methods rely 
Figure 4. Schematic representation of the action of diversifying selection. Adapted from [95]. Reproduced with 
permission from Elsevier Ltd, license number 3717271494244. 
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on measuring information within sequence alignments of protein-coding DNA [91]. The main parameter 
assessed is the ratio (ω) of the number of nonsynonymous nucleotide substitutions (i.e. that change the 
encoded aminoacid) per site (dN) over the number of synonymous nucleotide substitutions (i.e. with no 
aminoacid changing) per site (dS) (ω=dN/dS) [90]. The interpretation of the ω ratio is based on the 
principle that most mutations are synonymous and evolutionary neutral, i.e. without functional 
consequences. In that sense, a ω = 1 means that an aminoacid change is neutral and a ω < 1 will reflect 
negative selection (meaning that aminoacid change was probably deleterious and its fixation rate was 
reduced). Evidence for diversifying selection is inferred when ω is significantly higher than 1 [90]. Initial 
applications of the method averaged the ω ratio over all codons in a gene and thus only provided 
information for the whole-protein [100]. Nevertheless, the action of positive selection is thought to be 
aimed at only a few number of sites [101–103]. To address this matter, new statistical models were 
developed to allow estimation of different ω ratios in distinct codons [101,104]. In each model, the 
variation of ω over all sites can be described by a specific statistical distribution. A likelihood ratio test 
(LRT) is then used to evaluate what model fits better to the data. To check for positive selection, LRT can 
compare a model that does not admit ω ≤ 1 (null hypothesis) with one that admits ω > 1 (alternative 
hypothesis) [103]. Two pairs of models incorporated in Phylogenetic analysis by maximum likelihood 
(PAML) package were shown to be the most reliable for this purpose (null versus alternative hypotheses, 
respectively): M1a versus M2a and M7 versus M8 [105]. The LRT is statistically significant (null 
hypothesis rejected) when twice the log likelihood difference between the two compared models is above 
the previously described critical values of a chi-squared distribution with two degrees of freedom [105]. 
The parameters in the statistical distributions of M2a and M8 models are grouped into classes, with one 
of them allowing ω > 1 [105]. When this condition is met, a post-inference method designed Bayes 
Empirical Bayes (BEB) is used to calculate the probability of a codon to come from the class with ω > 1 
[106]. A more recent method named Fast Unbiased Bayesian AppRoximation (FUBAR) [107] also applies 
a codon model to infer the synonymous and the nonsynonymous substitution rates (designated as α and 
β by the authors, respectively). FUBAR differs from  PAML due to the adoption of some computational 
shortcuts and the use of a distinct method to assess site-specific posterior probabilities for being under 
diversifying selection, indicated as the posterior probability of β > α [107]. Codon models were previously 
shown to be powerful and robust in the absence of recombination [108]. Indeed, PAML and FUBAR have 
unveiled positively selected sites in human pathogens, such as in genes encoding for surface 
glycoproteins of the influenza H5N1 virus [109], as well as a specific siderophore in Pseudomonas 
aeruginosa [110]. PAML has also revealed sites under diversifying selection in the genome of M. 
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tuberculosis related to drug-resistance [111,112] and to other evolutionary pressures [111]. Particularly, 
evidences of positive selection were identified in a putative antigenic region, suggesting that human 
immune system can be responsible for the selection of some variants in the genome of the pathogen 
[111]. 
The role of T cells in the immune response against TB 
The immunity against TB is tightly dependent on T lymphocytes, namely CD4+ and CD8+ T cells [1,113]. 
Indeed, the low numbers of CD4+ T cells characteristic of HIV-patients are associated with high 
susceptibility to TB [114] and mice that are deficient in CD4+ T cells die rapidly from the disease [115]. 
CD8+ T cells also contribute to disease resistance in humans [116], rhesus macaques [117] and mice 
[115]. Owing to the importance of these two types of T lymphocytes in the control of TB, it is very relevant 
to detail the characteristics of the T cell-mediated TB protective immune responses. After aerosol 
inhalation, tubercle bacilli are phagocytized by antigen-presenting cells (APC) such as alveolar 
macrophages (AM) (Figure 5A) and interstitial dendritic cells [1]. On the surface of APC, peptides 
generated by proteolysis of M. tuberculosis proteins (i.e. the antigens) are bounded to major 
histocompatibility complex (MHC) proteins (also known as human leukocyte antigen [HLA] in humans). 
HLA class I molecules present antigenic peptides to CD8+ T cells and HLA class II molecules to CD4+ T 
cells (Figure 5B) [118]. T cell receptor then recognize a specific complex formed by the HLA molecule 
and the presented peptide (i.e. the T cell epitope) [119,120]. After this step, T cells can stimulate bacterial 
killing in macrophages by the secretion of inflammatory mediators such as interferon-gamma (IFN-γ) [1] 
(Figure 5A). Some T cells also differentiate into a memory phenotype that provide more rapid protection 
Figure 5. Key players in the immunity against TB. (A) Phagocytosis of M. tuberculosis and secretion of IFN-γ by T 
cells. Adapted from [122]. (B) Recognition of epitope-MHC II complex by a CD4+ T cell. Adapted from [121]. 
(A) (B)
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upon new contacts with the same pathogen peptide. This property turns T cells attractive to be explored 
in the context of vaccine design [113].   
Principles and techniques for T cell epitope discovery 
The formation of a epitope-HLA complex with the right affinity and stability is a strong requirement to  
elicit a T cell response [123]. This makes the step of formation of the epitope-HLA complex an important 
focus of epitope discovery. Nevertheless, identifying the epitope with proper characteristics is a difficult 
task. First, T cell epitopes can be derived from virtually all proteins expressed in an organism [124]. 
Second, HLA molecules can accommodate peptides of several lengths in their binding groove, i.e. 8-15 
amino acids in the case of HLA class I and 8-20 in HLA class II [125]. Laboratorial approaches to identify 
T cell epitopes rely on the synthesis of overlapping peptides encompassing antigens of interest. 
Synthesized peptides are then used to stimulate sensitized T cells ex vivo and the best epitope candidates 
are inferred through the quantification of correlates of T cell immune response, such as cytokine 
production [126] or T cell proliferation [127]. The complexity, time and cost of these experimental steps 
are huge constraints to a more widespread application [125]. 
In the last two decades, several computational methods were developed to analyse and model the 
properties of the immune system, giving rise to the field of immunoinformatics [124,128]. T cell epitope 
prediction, also known as reverse vaccinology [129], is a specific branch of immunoinformatics that offers 
a large potential to accelerate the process of epitope discovery [123]. The main principle of T cell epitope 
prediction is to find peptides with high binding affinity to HLA molecules, since these have more probability 
to be presented to T cells [130,131]. This pretension is complicated by the existence of thousands of 
HLA class I (HLA-DR, -DQ and -DP) and class II (HLA-DR, -DQ and -DP) alleles in the human population, 
each one with a distinct binding specificity [132]. Furthermore, HLA alleles have different frequencies 
across the worldwide population [133]. This means that a certain T cell epitope can elicit a response in 
some human populations but not in others [134]. Taking this into account, Bui et al. (2006) developed 
an algorithm that calculates the population coverage of an epitope, i.e. the fraction of individuals in a 
population in which it will be putatively effective [135].  
In addition to the HLA molecule, binding affinity also depends on the amino acid sequence of the antigen 
epitopes [136,137]. In the context of TB, it was previously shown that a large set of experimentally 
validated MTBC T cell epitopes are evolutionarily conserved [138]. However, the known repertoire of 
MTBC epitopes is likely to be incomplete, thus impairing a full view of the evolution across the MTBC 
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immunoproteome [139,140]. In fact, only a small percentage of M. tuberculosis proteins has been shown 
to include epitopes [140,141].  
Among the variety of in silico algorithms that predict T cell epitopes (reviewed in [123] and [142]), the 
most accurate ones are trained with large sets of epitopes with experimentally determined binding affinity 
[143]. Particularly, NetMHCpan [144] and NetMHCIIpan [145] were shown to be the best overall 
predictors in independent benchmarks [146–148]. Both methods only need the amino acid sequences 
of interest as input to generate predictions for all known HLA molecules. Quantitative prediction of the 
binding affinity is extrapolated from a training data set through advanced computational algorithms 
[144,145]. It is also possible to predict the binding affinity to HLA proteins with no known experimental 
binding data on the basis of other HLA molecules with similar binding pocket residues [143]. 
The bulk of the immune response is aimed at a small fraction of the possible epitopes [119,120], a 
feature called immunodominance [149]. In this regard, it was described that a higher kinetic stability of 
the HLA-peptide complex is a good predictor for immunodominance in both HLA class I [150] and HLA 
class II [151–153]. In M. tuberculosis, besides antigen 6-kDa early secretory protein antigenic target 
(ESAT-6) [154], only a few other immunodominant epitopes were validated in TB patients [155]. Another 
factor that affects immunodominance is the relative abundance of peptides available for binding. Genes 
with high in vivo expression levels in the context of infection constitute good candidates for the 
identification of relevant T cell epitopes since their encoded peptides are more likely to be presented than 
other low abundance peptides with similar HLA-binding affinity and stability [156]. In the M. tuberculosis 
genome, Talaat and colleagues found a genomic region of 44,849 nucleotides that harbour several genes 
highly expressed in vivo [157,158]. The region is constituted by 43 contiguous genes and was designated 
as in vivo-expressed genomic island (iVEGI) [157]. Interestingly, iVEGI is upregulated upon infection in 
wild-type mice models but not in immune compromised animals or during in vitro growth of M. 
tuberculosis [157]. This suggests a role for iVEGI in the interaction with host immune cells, highlighting 
T cell responses as a possible driving force of natural selection in this region. 
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AIMS 
Co-evolution between humans and M. tuberculosis strains have produced numerous examples of clinical 
and epidemiological heterogeneity (reviewed in [159] and [88]). However, the molecular basis underlying 
host-pathogen interactions in TB remain poorly understood. Indeed, despite the critical importance of T 
cells to the control of TB, the impact of the genetic diversity selected during the MTBC evolution on the 
full repertoire of M. tuberculosis T cell epitopes is poorly study. Still, the existing studies show evidence 
for genetic variation in known T cell epitopes [138] and for diversifying selection in a predicted antigenic 
region [111]. The identification and functional characterization of the immune responses elicited by 
variable epitopes are of critical importance from a vaccine-development point of view since these might 
correlate with protective responses. Highly in vivo-expressed genes mediate most of the host-pathogen 
interactions and are thus thought to be major targets of immune-related selective pressure. Therefore, 
M. tuberculosis iVEGI, a genomic region found to be upregulated in vivo in immunocompetent mice 
models of infection [157], is a good candidate region to identify these epitopes.   
Taking this into account, the aim of this thesis is to analyse the iVEGI for evidence supporting the presence 
of M. tuberculosis epitopes under T cell driven positive selection. In order to address this goal, a research 
workflow composed of four main tasks was designed:  
(i) Comparative genomics analysis, to investigate the nucleotide diversity of 43 genes highly expressed in 
in vivo models of infection;   
(ii) Detection of diversifying selection, to search for signatures of molecular adaptation among the genetic 
diversity unveiled at (i);  
(iii) Prediction of CD4+ and CD8+ T cell epitopes in protein sequences encoded by genes with sites under 
diversifying selection; 
(iv) In vitro HLA-peptide binding assays, to provide the experimental validation of the best candidates from 
preceding tasks.  
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RESULTS 
High nucleotide diversity and evidence for diversifying selection in the iVEGI 
The in vivo expression pattern of iVEGI suggests a role in host-pathogen interactions during infection and 
the consequent possibility of evolution in response to host pressures. To investigate this, the sequence 
diversity on the iVEGI was characterized. This region was extracted from the genomes of 270 isolates 
belonging to the seven MTBC lineages and comparative genomics analysis was performed. The iVEGI 
was significantly more diverse (π = 5.04 x 10-4, p < 0.001) than the rest of the genome (π = 2.65 x 10-
4), with the majority of the genes analysed (21 out of 40) displaying levels of nucleotide diversity (π) above 
the genome-wide mean (Figure 6A). The level of genetic diversity in the iVEGI was very similar (p > 0.05) 
between ‘ancient’ (lineages 1, 5, 6 and 7; π = 3.42 x 10-4) and ‘modern’ (lineages 2, 3 and 4; π = 3.62 
x 10-4) MTBC strains. This is in contrast with the whole-genome data, which showed that the ‘ancient’ 
lineages (π = 3.10 x 10-4) had a significantly higher nucleotide diversity level (p < 0.001) when compared 
to the ‘modern’ lineages (π = 1.82 x 10-4) (Figure 6B). A more detailed analysis revealed a total of 320 
SNPs, of which 291 were located in coding regions and 29 in intergenic regions (Figure 6C and 
Supplementary Table 1). SNPs were detected in all the seven MTBC lineages and with highly variable 
frequencies. Homoplastic SNPs were also found, 13 located in genes and two in intergenic regions 
(Supplementary Table 1). 
 
 
 
 
 
16 
 
Considering that SNPs under diversifying selection may reflect targets of molecular adaptation driven by 
host-related pressures, the iVEGI genes were screened for diversifying selection with PAML and FUBAR 
[105,107]. The site models M2a and M8 included in PAML package were applied and Bayes Empirical 
Bayes (BEB) analysis revealed significant evidence for diversifying selection (M2a pp > 0.95 or M8 pp > 
0.95) in seven codon sites corresponding to amino acid positions 186 of LprP (M2a pp = 0.928 and M8 
pp = 0.977), 666 of AccA2 (M2a pp = 0.999 and M8 pp = 1.000), 51 and 233 of AccD2 (M2a pp = 
0.901 and M8 pp = 0.953; M2a pp = 0.997 and M8 pp = 0.999, respectively), 54 and 68 of Rv0990c 
(M2a pp = 0.957 and M8 pp = 0.982; M2a pp = 0.960 and M8 pp = 0.983, respectively) and 81 of RimJ 
Figure 6. Comparative genomics analysis of the iVEGI. (A) Nucleotide diversity of individual iVEGI genes. (B) Nucleotide diversity (π) of the genome (in 
blue) versus iVEGI (in orange) in strains from the ‘ancient’, ‘modern’ and all the seven MTBC lineages. (C) Schematic representation of the sequence variation 
found in iVEGI. The relative frequency of the nucleotide substitutions in each of the seven MTBC lineages (right yy axis) is represented on the left yy axis. 
Genomic positions (xx axis) are according to the reference genome H37Rv (GenBank accession number NC00962.3). Pe_pgrs16, pe_pgrs17 and pe_pgrs18 
were excluded from the analysis and are not represented (stroke line). ** p < 0.01; *** p < 0.01. 
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(M2a pp = 0.950 and M8 pp = 0.981) (Table 1). FUBAR identified four additional putative targets of 
diversifying selection (pp (β>α) > 0.9) in amino acid residues 169 of Rv0987 (pp β>α = 0.941); 191 of 
Rv0988 (pp β>α = 0.967); 141 of GrcC2 (pp β >α = 0.942) and 303 of Rv0996 (pp β>α = 0.918) 
(Table 1). An overlap between the predictions of PAML and FUBAR was found for the amino acid 233 of 
AccD2. To test a possible influence of recombination, nucleotide sequences were analysed with RDP, 
GENECONV and Bootscan, with none of the methods detecting signals supportive of recombination (data 
not shown). Overall, evidences for diversifying selection were detected by PAML or FUBAR in 11 codons 
of nine distinct iVEGI genes (Table 1). These data support high levels of nucleotide diversity and the 
occurrence of targeted events of diversifying selection in the iVEGI. 
 
 
BEB, Bayes Empirical Bayes; pp, posterior probability; β, nonsynonymous substitution rate; α, synonymous substitution rate; *p < 0.05; **p < 
0.01 
a pp above 0.900 considered as highly supportive of diversifying selection by FUBAR. 
Table 1. Amino acid substitutions under diversifying selection in iVEGI. 
Gene 
name 
Genomic 
position 
Gene 
position 
Amino acid 
substitution 
PAML 
FUBAR 
M2a M8 
BEB pp ω>1 ω ratio ± SE BEB pp ω>1 ω ratio ± SE β-α pp β>α 
lprP 
(Rv0962c) 
1074996 557 L186P 0.928 8.138 ± 2.683 0.977* 8.561 ± 2.145 4.798 0.876 
accA2 
(Rv0973c) 
1083755 1996 S666P 0.999** 8.705 ± 1.835 1.000** 7.992 ± 1.954 2.658 0.788 
accD2 
(Rv0974c) 
1087193 153 K51N 0.901 7.778 ± 2.910 0.953* 8.006 ± 2.516 3.300 0.819 
1086648 698 R233L 0.997** 8.482 ± 1.973 0.999** 8.341 ± 2.015 6.601 0.930ª 
Rv0987 1103046 505 V169L 0.289 1.231 ± 1.276 0.361 1.242 ± 1.220 7.789 0.941ª 
Rv0988 1105686; 1105687 571;572 L191A 0.704 3.977 ± 3.117 0.815 4.316 ± 3.069 7.887 0.967ª 
grcC2 
(Rv0989c) 
1106961;1106962 421;422 V141L/A 0.831 5.613 ± 3.174 0.925 5.749 ± 2.902 7.140 0.942ª 
Rv0990c 
1107940 160 A54S 0.957* 7.555 ± 2.542 0.982* 7.333 ± 2.484 4.183 0.861 
1107897 203 A68V 0.960* 7.571 ± 2.524 0.983* 7.340 ± 2.477 4.422 0.881 
rimJ 
(Rv0995) 
1111852 241 D81Y 0.951* 6.780 ± 2.667 0.981* 6.428 ± 2.570 3.516 0.840 
Rv0996 1113290;1113292 907;909 Q303E/H 0.696 4.076 ± 3.210 0.827 4.595 ± 3.204 6.693 0.912a 
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Specific iVEGI variants under diversifying selection impact T cell epitope 
prediction 
The sustained high in vivo expression of iVEGI in mouse models of M. tuberculosis infection [157,158] 
makes its encoded proteins good candidates for antigen presentation. Taking this into account and 
considering its genetic diversity, the genomic island was next tested for the presence of unknown T cell 
epitopes that could be the underlying cause of diversifying selection. For this purpose, the binding affinity 
of the peptides overlapping the iVEGI sites under diversifying selection was predicted to a set of 72 class 
I and 41 class II HLA molecules (Supplementary Table 2). The analysis was performed with NetMHCpan 
[144] and NetMHCIIpan [145]. A total of 1530 putative high binding affinity peptides were identified, 
including 244 for class I HLA and 1286 for class II HLA. To allow class I versus class II comparisons, the 
results were normalized for the number of peptide lengths and HLA molecules tested and expressed as 
the percentage of the maximum possible number of high binding affinity peptides (Figure 7 and 
Supplementary Figure 1). The majority of the sites with significant evidences for being under diversifying 
selection (eight out of 11) were found to be included in regions encoding peptides predicted to bind with 
high affinity to at least one HLA of both classes (Figure 7A). The exceptions were the amino acids AccA2 
S666, with no predicted high binding affinity peptides, and AccD2 K51 and Rv0990c A68, with high 
binding affinity peptides detected only to class I HLAs. HLA class II predictions identified in mean five 
times more immunogenic peptides than HLA class I predictions (Figure 7A). Interestingly, about 90% of 
the putative CD4+ T cell epitopes were concentrated in the overlapping regions of three sites (Rv0987 
V169, Rv0988 L191 and Rv0996 Q303). 
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To evaluate the functional impact of sequence diversity on T cell epitope prediction, the HLA-binding 
affinity of wild-type peptide sequences was compared to that of the variant peptides under selection 
(Figure 7B). Variations in class II HLA were highly predominant and responsible for 84% of the total 
Figure 7. Immunoinformatics analysis of the sites under diversifying selection in iVEGI. (A) Number of putative 
CD4+ and CD8+ T cell epitopes in amino acid sequences including sites under diversifying selection. High binding affinity 
peptides were predicted by NetMHCpan and NetMHCIIpan to a representative set of HLA class I (in blue) and class II (in red) 
alleles (Supplementary Table 2). The number of predicted immunogenic peptides is represented as percentage of the total 
possibilities for each HLA class (Supplementary Figure 1). (B) Variation in the number of high binding affinity peptides due to 
diversifying selection in the iVEGI. a More than one amino acid substitution in the same codon; only the substitution resulting 
in the highest variation was represented. 
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differences registered. Strikingly, three substitutions (AccD2 R233L, Rv0987 V169L and Rv0988 L191A) 
contributed to 72% of all the predicted alterations in class II HLA-binding (Figure 7B). Indeed, variants 
AccD2 R233L and Rv0987 V169L increased the number of potential CD4+ T epitopes by 2.5% and 2.1%, 
respectively. Contrarily, Rv0988 L191A decreased this number by 2.2% when compared to the wild-type 
sequence. Overall, the data revealed three amino acid substitutions (AccD2 R233L, Rv0987 V169L and 
Rv0988 L191A) with high probability to be under CD4+ T cell driven diversifying selection. 
Figure 8. Variations in the worldwide population coverage in sites under diversifying selection. The percentage 
of the human population with potential to recognize predicted T cell epitopes (worldwide population coverage) was estimated 
for HLA class I (in blue) and HLA class II (in red). The difference between the population coverage of the variants under 
diversifying selection relative to the wild-type is on the yy axis. a More than one amino acid substitution in the same codon; 
only the substitution that resulted in the highest variation was represented. 
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Geographic correlations between population coverage and MTBC lineage 
frequency 
T cell epitopes might be differentially recognized by diverse individuals due to the variable frequencies of 
HLA alleles across the human population, thus resulting in distinct population coverage. For this reason, 
the fraction of the human population with potential to recognize the putative epitopes under study 
(worldwide population coverage) was predicted. Next, the variation resulting from the presence of amino 
acids under diversifying selection was calculated (Figure 8 and Supplementary Table 3). Despite the low 
number of high binding affinity peptides to HLA class I (Figure 7), the highest alterations in population 
coverage imposed by the variant epitopes were found for HLA class I (Figure 8). Of particular note were 
four amino acid substitutions (LprP L186P, AccD2 R233L, Rv0988 L191A and RimJ D81Y) which showed 
a high impact on the HLA class I worldwide population coverage (-26%, +16%, -41% and +15%, 
respectively, as compared to the wild-type sequence) (Figure 8). 
The largest variations in class II HLAs worldwide population coverage were attributed to AccD2 R233L 
and Rv0987 V169L (which were expected to increase coverage by 9% and 11%, respectively) and to 
Rv0988 L191A (expected to decrease the coverage by 11%). The analysis was expanded by investigating 
if the regional variations in population coverage were associated with the geographic distribution of the 
MTBC lineages harbouring the selected variants (Figure 9). For that purpose, the frequency of the MTBC 
lineages and the alterations in regional population coverage induced by the variants under diversifying 
selection were compared across 15 world geographic regions (Supplementary Figure 2). No correlations 
were found for the HLA class I. In contrast, three statistically significant correlations were found between 
the variations in HLA class II population coverage for AccD2 R233L (rτ = 0.39, p < 0.05), Rv0987 V169L 
(rτ = 0.47, p < 0.05) and Rv0988 L191A (rτ = -0.41, p < 0.05) and the frequency of lineage 1 and lineage 
2 strains (Figure 9 and Supplementary Table 4). AccD2 R233L occurred in all the lineage 1 strains 
analysed (Figure 6C and Supplementary Table 1) and the variant amino acid induced a calculated 
increase in regional population coverage ranging from 1% in Central America to nearly 30% in Southeast 
Asia (Figure 9A). This increase in population coverage significant and positively correlated with the 
percentage of lineage 1 frequency in the 15 tested regions (graph in Figure 9A). Rv0987 V169L was 
found in 10% of the lineage 1 strains and 8% of the lineage 2  strains analysed (Figure 6C and 
Supplementary Table 1) and resulted in a predicted increase of the regional population coverage ranging 
from 3% in Central America to 29% in Southeast Asia (Figure 9B). The estimated increase in coverage 
was also significant and positively correlated with the regional prevalence of lineage 1 and 2 strains (graph 
in Figure 9B). In contrast, Rv0988 L191A, that was found in 69% of the lineage 2 strains (Figure 6C and 
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Supplementary Table 1), was estimated to decrease the regional population coverage from 3% in Central 
America to 29% in Southeast Asia (Figure 9C). This was significant and negatively correlated with the 
regional frequency of the lineage 2 strains (graph in Figure 9C). Overall, the results suggest that the 
amino acid substitutions AccD2 R233L, Rv0987 V169L and Rv0988 L191A were likely relevant to the 
sympatric adaptation of MTBC strains to certain host populations. 
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Figure 9. Association between differential population coverage of predicted epitopes and the geographic 
distribution of the MTBC. The frequency (in pie charts) of the MTBC lineages harboring sites under diversifying selection 
(in xx axis of each graph) correlated with the variations in population coverage due to differential binding to human HLA class 
II (green and red color gradients) of peptides harbouring three amino acid substitutions: (A) AccD2 R233L (rτ = 0.39, p < 
0.05); (B) Rv0987 V169L (rτ = 0.47, p < 0.05) and (C) Rv0988 L191A (rτ = -0.41, p < 0.05). 
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In vitro validation of the predicted CD4+ T cell epitopes under diversifying 
selection 
Typical T cell epitopes are expected to bind with high affinity and stability to an HLA molecule [123]. 
Thus, large alterations in the HLA-binding properties are anticipated in epitopes under T cell driven 
diversifying selection. Taking this into account, the in vitro HLA-binding affinity and stability were 
compared for the set of wild-type and variant peptides that i) were predicted to be under diversifying 
selection; ii) showed large variation in the predicted HLA-binding affinity and iii) impacted the population 
coverage and correlated with the geographical distribution of the MTBC lineages. This set was formed by 
six peptides with the amino acid substitutions AccD2 R233L, Rv0987 V169L and Rv0988 L191A. The 
HLA class II DRA1*01:01 DRB1*01:01 was chosen for the in vitro assays since this was the HLA with 
the broadest population coverage [160] among the ones with variable predicted binding affinity. The 
binding affinity and stability of each peptide was compared to a validated DRB1*01:01 CD4+ T cell epitope 
of the M. tuberculosis ESAT-6 protein [155]. The results confirmed the variant forms of AccD2228-241 and 
Rv0987164-177, but not of Rv0988185-202, as being epitopes with strong binding affinity to DRB1*01:01. In 
agreement with the in silico analysis, radical alterations (> 58%) in the binding affinity between wild-type 
and variant peptides were observed for AccD2228-241 and Rv0987164-177 (Figure 10). Most importantly, the 
variant AccD2228-241 peptide, in addition to displaying a binding affinity as high as ESAT-63-17, also formed 
a highly stable complex with DRA1*01:01 DRB1*01:01. This suggests that the variant AccD2228-241, but 
not the wild-type peptide, has the potential to function as a previously unidentified immunodominant CD4+ 
T cell epitope in individuals expressing the HLA DRA1*0101 DRB1*01:01. 
Figure 10. In vitro validation of the candidate CD4+ T cell epitopes under diversifying selection. Amino acid substitutions with the highest impact 
on HLA class II binding predictions (AccD2 R233L, Rv0987 V169L and Rv0988 L191A) were subjected to in vitro confirmation of the estimated HLA-binding 
affinity. The HLA class II molecule with the broadest population coverage among the ones with variable predicted binding affinity (DRA1*01:01 DRB1*01:01) 
was used. The binding affinity of wild-type and variant peptide sequences was measured at 0 h and 24 h after incubation with the DRA1*01:01 DRB1*01:01 
protein and compared with a validated M. tuberculosis CD4+ T epitope (ESAT-63-17). The stability index of the different DRA1*01:01 DRB1*01:01-peptide 
epitope complexes was also evaluated. 
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DISCUSSION 
Control of TB, a global disease that affects millions of people every year, highly relies on the development 
of better preventive strategies as the only vaccine in use (BCG) is of limited efficiency [5,6]. In fact, much 
effort has been put on the development of new vaccines but so far the results have been at best similar 
to BCG [161,162]. To achieve better outcomes, a deep understanding of the characteristics of protective 
immune responses and of how they are triggered and modulated is critical [162,163]. In this context, 
and considering that the efficiency of host T cell-mediated immunity is determinant for infection control 
[1,113], it is greatly relevant to obtain a full picture of the factors that might influence T cell responses in 
TB. Among these factors, the genetic and phenotypic diversity associated with the MTBC has been 
neglected. Indeed, several studies showed that strains of M. tuberculosis differently interact with innate 
immune cells [64,65,69,164,165], thus potentially being able to modulate the outcome of the acquired 
immune response [166]. Another factor with a potential impact on the type and quality of T cells 
responses is the existence of varying epitopes within the MTBC. It has been previously described that 
several T cell epitopes are evolutionarily hyperconserved [138], suggesting that the T cell responses 
induced in the host are similar across the MTBC diversity. However, the sympatric associations between 
MTBC lineages and human populations [48] and its disruption in HIV-1 infected individuals [114] suggests 
that at least an unknown set of relevant and variable MTBC CD4+ T cell epitopes may exist. Furthermore, 
considering the long co-evolution of MTBC with its human host [51,88], it is likely that the host immune 
system represents a strong pressure shaping the evolution of the MTBC complex and namely at the level 
of the epitope-HLA interaction. In fact, different HLA haplotypes have been associated with resistance or 
susceptibility to TB caused by uncharacterized strains [167–169]) or even associated to TB caused by 
specific MTBC phylogenetic taxa [170]. In this thesis, a pipeline of molecular evolution, 
immunoinformatics and in vitro techniques was applied to reveal novel T cell epitopes in MTBC, taking 
into consideration the genetic variation within MTBC and its phylogeographic adaptation to the human 
host. Herein presented data constitute the first evidences for T cell driven diversifying selection in MTBC, 
namely within the genomic island iVEGI.  
The iVEGI is a good candidate region within the M. tuberculosis genome for the discovery of MTBC-varying 
epitopes, due to its in vivo expression profile [157] and high genetic diversity as shown herein. Screening 
in vivo-expressed regions for the discovery of novel M. tuberculosis antigens has previously allowed the 
successful identification of a novel antigen encoded by Rv2034 [171]. The iVEGI contains several genes 
implicated in the survival and pathogenesis [158] of M. tuberculosis and with prolonged high expression 
26 
 
levels in immunocompetent animal models of TB infection but not in immunosuppressed animals or 
during in vitro growth [157]. Data for high genetic diversity in the iVEGI were firstly reported in a study 
comparing 20 genomes across four MTBC lineages, which highlighted a three genes operon (Rv0986-
Rv0988) in this region with high SNP density [89]. Using 270 genomes from all the known seven MTBC 
lineages, it was revealed that a total of 21 genes in the iVEGI had a level of nucleotide diversity above the 
whole-genome average. The results also showed that SNPs in the iVEGI were evenly distributed across 
the MTBC lineages, which is in contrast with the genome-wide data in support for higher genetic 
conservation among the ‘modern’ (lineages 2, 3 and 4) when compared to ‘ancient’ lineages (lineages 
1, 5, 6 and 7). This finding points to differences in the evolutionary process of this particular region. In 
addition, evidence supporting the action of diversifying selection was found in 11 iVEGI loci. Thus, genetic 
diversity and molecular evolution analyses strongly support the involvement of this genomic island in the 
long-term evolution of the MTBC population. Subsequent immunoinformatics data highlighted T cells as 
one of the driving forces for this evolution. Some variant iVEGI peptides were predicted to have differential 
binding affinity to class I or class II HLAs, with the more pronounced alterations found in HLA class II. 
This is congruent with previous studies showing that the contribution of CD4+ T cells for the immunity 
against TB is more relevant than the one of CD8+ T cells [115,172]. Distinct host-pathogen interactions 
could be the cause of failure in producing a universal vaccine with high worldwide population coverage. 
Indeed, three distinct TB vaccine candidates were found to have considerably different overall population 
coverage, thus threatening their efficacy in certain regions of the globe [173]. In this context, much of the 
existing T cell epitope discovery studies in M. tuberculosis field have been using HLA molecules with high 
frequency in white individuals, which is likely to have a negative impact in the efficacy of the vaccine in 
several world regions with high TB burden [141]. The in silico-based approach followed in this thesis 
addresses this bias by including in the predictions HLA alleles that are predominant in TB endemic 
regions. The largest variations in HLA-binding affinity were concentrated in three specific codons of three 
distinct iVEGI-encoded proteins and were estimated to have a large impact in the world population 
coverage. Interestingly, for these three amino acid substitutions, there were significant correlations 
between the alterations in HLA class II population coverage and the frequency of the MTBC strains 
harbouring the selected variants. Therefore, the referred substitutions may represent evolutionary 
markers in MTBC of sympatric adaptation driven by CD4+ T cells. The binding affinity and the stability of 
wild-type and variant forms of the peptides containing these markers was measured in vitro. The in vitro 
assays showed that the single amino acid substitutions predicted to be under diversifying selection in 
both AccD2228-241 and Rv0987164-177 induced large alterations (> 58%) in the binding affinity between wild-
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type and variant peptides, which was not observed for Rv0988185-202. However, the most striking finding 
was that although the wild-type sequence of AccD2228-241 did not bind to DRB1*01:01, the lineage 1-
associated variant peptide displayed a level of binding affinity and stability as high as the experimentally 
confirmed immunodominant epitope ESAT-63-17 [155]. Since the stability of the HLA-peptide complex was 
associated with immunodominance [150–153], the variant AccD2228-241 peptide may constitute a 
relevant lineage-specific CD4+ T cell epitope.  
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CONCLUSION AND FUTURE PERSPECTIVES 
The workflow described in this thesis allowed the identification of predicted T cell epitopes under 
diversifying selection in iVEGI, their study in terms of envisaged HLA-binding, impact in worldwide 
population coverage and geographic association between the human population and MTBC and, finally, 
the functional validation of the most promising candidates. The use of these approaches provided 
evidence for the existence of HLA-restricted T cell epitopes evolving under diversifying selection across 
the MTBC in response to immune pressure. From the 11 amino acid substitutions predicted to be under 
diversifying selection in iVEGI, three (AccD2 R233L, Rv0987 V169L and Rv0988 L191A) were associated 
with immune system pressure in silico. Of this, strong evidences to be a variable T cell epitope were 
confirmed in vitro for a peptide encompassing AccD2 R233L. However, T cells cannot be discarded as 
drivers of Rv0987 V169L and Rv0988 L191A, as performing the in vitro binding assays with other HLA 
predicted to have variable binding affinity (or even with other peptide) could yield different results. For the 
eight remaining sites, the responsible selective pressure has yet to be uncovered. Protein signature 
recognition tools such as InterProScan [174] could be the starting point to understand the cause and 
importance of these substitutions to M. tuberculosis. These tools perform homology search for conserved 
motifs, enzymatic active sites and many other features [174], and are thus a vital aid in the functional 
characterization of a protein. 
The variant form of AccD2228-241 was confirmed to have different binding affinity and stabilities 
comparatively to the wild-type. Nevertheless, further experiments are needed to ensure that the peptide 
is presented to T cells and is differentially immunogenic in humans infected with lineage 1 strains. To 
achieve this, wild-type and mutant peptides could be synthesised and used to stimulated blood collected 
from TB patients that i) express the HLA class II of interest and ii) were infected with lineage 1 strains. 
Assuming that memory T cells are created upon the recognition of the AccD2228-241-DRB1*01:01 complex, 
differences in the levels and type of T cell responses are expected upon stimulation. For instance, this 
could be assessed by the quantification of cytokines known to be associated with TB disease, such as 
IFN-γ and interleukin-10 (IL-10) [1]. The implications of this study can also be extended to vaccination 
field, i.e. the BCG vaccine strains harbour the wild-type AccD2228-241 peptide that was found not to bind 
to DRB1*01:01. It is thus tempting to speculate that boosting the BCG-induced immune response with 
the variant AccD2228-241 could influence the protection to infections caused by lineage 1 MTBC strains. 
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Overall, the results presented in this thesis contributed to highlight T cells as one of the drivers in the 
evolutionary process of highly expressed M. tuberculosis genes, with consequences in the host-pathogen 
sympatric associations. The findings further support the impact of MTBC diversity in host immune-
responses and pave the way to the discovery of novel MTBC lineage-specific epitopes. A better 
understanding of the molecular targets under T cell driven evolution will offer unprecedented tools in the 
development of TB preventive and therapeutic strategies with broader effectiveness. 
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MATERIALS AND METHODS 
Sequence retrieval 
To comprehensively represent all the seven known phylogenetic lineages of the MTBC, two previously 
described M. tuberculosis whole-genome sequence sets [51,111] were combined with five additional M. 
tuberculosis genomes publically available in the databases (Beijing/NITR203, CAS/NITR204, 
EAI5/NITR206, Haarlem/NITR202 and NCGM2209; GenBank accession numbers NC_021054, 
NC_021193, NC_021194, NC_021192 and NZ_DF126614, respectively), resulting in a total of 270 
MTBC genomes (48 from lineage 1, 49 from lineage 2, 40 from lineage 3, 95 from lineage 4, 17 from 
lineages 5, 17 from lineages 6 and 4 from lineage 7). The region of 44,849 nucleotides known as iVEGI 
[157] was extracted with MegaBlast [176] from the 270 M. tuberculosis genomes using H37Rv (GenBank 
accession number NC_000962.3) as the reference. Three pe_pgrs genes present in the iVEGI region 
(pe_pgrs16, pe_pgrs17 and pe_pgrs18) displayed high homology between its coding and intergenic 
repetitive regions [177,178] and were thus excluded from the analysis due to the technical difficulties in 
obtaining reliable nucleotide sequences. Multiple sequence alignments were performed by MUSCLE 
[179], with subsequent manual curation.  
Nucleotide diversity and recombination tests  
Whole genome and iVEGI nucleotide sequences were divided into 100 equal parts and its nucleotide 
diversity (π) was calculated using MEGA-CC [180]. Statistical significance in the comparisons among 
groups was assessed with t-test in SPSS v22. Nucleotide sequences of iVEGI were screened for 
recombination events through the automated RDP, GENECONV and Bootscan algorithms implemented 
in RDP v4.36 software [181].  
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Analysis of diversifying selection 
Signatures of diversifying selection were detected by the CODEML program included in PAML package 
[105] and by FUBAR [107] implementation available on the Datamonkey web server 
(http://www.datamonkey.org) [182]. Inference of diversifying selection in CODEML was performed 
through pairwise comparison of site models that do not allow ratios of nonsynonymous to synonymous 
substitutions greater than one (ω>1) with an alternative model that allow ω>1 (M1-M2a and M7-M8), by 
a likelihood ratio test (LRT). As recommended [105], a Bayes empirical Bayes (BEB) approach [106] was 
used to calculate the posterior probability (BEB pp) of each codon to be under diversifying selection only 
when LRT values > 5.99 (meaning that the model admitting selection fitted better to data at a 5% 
significance level). The minimum requirement for a given site to be considered as evolving under 
diversifying selection was BEB pp > 0.95 in one of the M2a or M8 CODEML models. In FUBAR, the 
posterior probability of the nonsynonymous substitution rate (β) to be greater than the synonymous 
substitution rate (pp β>α) was considered as indicative of diversifying selection only for pp β>α values 
above 0.9. 
T cell epitope prediction  
iVEGI regions comprising amino acid residues under diversifying selection were investigated for the 
presence of CD4+ T and CD8+ T cell epitopes with NetMHCpan 2.8 [144] and NetMHCIIpan 3.0 [145], 
respectively. These methods were chosen since they were reported to be the best overall predictors [146–
148]. A comprehensive set of HLA alleles (Supplementary Table 2) was selected based on its high 
prevalence in the human population worldwide [183,184] or in TB endemic regions [173]. HLA-C alleles 
were not selected for the HLA class I predictions due to its limited polymorphism and lower expression 
levels (about 90% less) comparatively to HLA-A and HLA-B [185]. Regarding HLA class II, HLA-DP and 
HLA-DQ loci were not considered since the predictions are thought to be less reliable due to few 
experimental binding data available [145]. On the –DR locus, only DRB1 alleles were used, as they bind 
the majority of the M. tuberculosis epitopes and were described to be five times more expressed than 
other DR alleles [186]. Half maximal inhibitory concentrations (IC50) < 50 nM or rank scores < 0.5% were 
used as cutoff for high binding affinity peptides. All peptide lengths available were used, for both HLA 
class I (peptides of 8-14 amino acids) and HLA class II (peptides of 9-19 amino acids). To allow 
comparison, a normalization to the number of peptide lengths and HLA molecules tested was applied 
and the results were expressed as the percentage of the maximum possible number of high binding 
 33 
 
affinity peptides (Supplementary Figure 1). In cases of more than one amino acid substitution per codon, 
only the substitution with the highest impact on the predictions was represented in the figures.  
Assessment of the worldwide population coverage and the geographic 
distribution of the MTBC 
The fraction of the human population with the ability  to recognize the predicted epitopes (worldwide 
population coverage) was estimated using the implementation of a previously described algorithm [135] 
at the Immune Epitope Database (http://tools.immuneepitope.org/tools/population/iedb_input) [160]. 
The input data were the HLA alleles with at least one high binding affinity peptide overlapping the selected 
sites (Supplementary Table 3). The frequency of the MTBC lineages (n = 41974 strains) across 15 
geographic regions (Supplementary Figure 2) was obtained from the SITVITWEB database [44]. Lineages 
were assigned to spoligotype data in accordance with the literature [187]. Unknown spoligotypes or the 
ones with regional frequencies below 1% were excluded from the analysis. The correlation between 
variations in the population coverage and the frequency of MTBC lineages was evaluated with the non-
parametric Kendall’s Tau (τ) test in SPSS Statistics v22. A p-value < 0.05 was applied as threshold for 
statistical significance.  
In vitro HLA-binding assays 
Candidate epitopes were tested for their binding affinity to DRA*01:01 DRB1*01:01 with the ProImmune 
REVEAL® HLA-peptide binding assay. All the peptides were synthetized with high purity (Supplementary 
Table 5). Binding affinity was determined as a function of the signal generated by a fluorescently labelled 
antibody against the native conformation of the HLA-peptide complex. A binding score was calculated for 
each peptide by comparison with a previously validated (both in vitro and in TB patients [155]) CD4+ T 
cell epitope (ESAT-63-17). Measurements were conducted at 0 and 24 h following incubation at 37°C. To 
obtain the stability index of the HLA-peptide complex, approximated half-life times were derived through 
a one-phase dissociation equation and subsequent multiplication by the binding score of each peptide. 
HLA-peptide complexes with resulting values ≥ six were considered to be highly stable.
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SUPPLEMENTARY DATA 
Single-nucleotide substitutions found in iVEGI  
 
Supplementary Table 1. Single-nucleotide substitutions found in iVEGI across 270 MTBC strains from all known lineages. 
Gene/intergenic 
region 
Common 
name 
Genome 
position 
Nucleotide 
substitution 
Type 
Amino acid 
substitution 
SNP frequency (%) 
dbSNPa TBDBb tbvarc 
Lineage 1 Lineage 2 Lineage 3 Lineage 4 Lineage 5 Lineage 6 Lineage 7 
Rv0960 - 1073704 G -> A Nonsynonymous A54T 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0960 - 1073716 C -> T Nonsynonymous R58W 31.3 0.0 0.0 0.0 0.0 0.0 0.0 rs157705827 x x 
Intergenic_Rv0960-
Rv0961 
- 1074039 C -> T - - 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0961 - 1074152 G -> T Nonsynonymous A27S 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0962c lprP 1074558 A -> G Nonsynonymous L186P 0.0 0.0 0.0 3.2 0.0 0.0 0.0 rs157727929 x x 
Intergenic_Rv0962c-
Rv0963c 
- 1075269 C -> T - - 0.0 0.0 0.0 4.6 0.0 0.0 0.0 
rs1577058883; 
rs157727947 
x x 
Intergenic_Rv0962c-
Rv0963c 
- 1075279 C -> T - - 0.0 0.0 0.0 18.3 0.0 0.0 0.0 rs157705884 x x 
Rv0963c - 1075584 C -> T Nonsynonymous G172R 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0963c - 1075618 G -> A Synonymous S160S 22.9 0.0 0.0 0.0 0.0 0.0 0.0 rs157705894 x x 
Rv0963c - 1075766 G -> A Nonsynonymous P111L 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0963c - 1075904 T -> C Nonsynonymous D65G 0.0 8.2 0.0 0.0 0.0 0.0 0.0   x 
Rv0963c - 1075986 C -> G Nonsynonymous A38P 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0963c - 1075997 C -> G Nonsynonymous R34P 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0963c - 1076020 C -> A Nonsynonymous K26N 0.0 0.0 0.0 1.1 0.0 0.0 0.0 rs157705937 x x 
Rv0963c - 1076052 T -> G Synonymous R16R 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
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Rv0964c - 1076196 T -> C Stoplost X161W 0.0 0.0 0.0 0.0 0.0 5.9 0.0    
Rv0964c - 1076309 T -> G Nonsynonymous T124P 0.0 0.0 0.0 6.3 0.0 0.0 0.0 rs157705967 x x 
Rv0964c - 1076532 G -> A Synonymous I49I 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Intergenic_Rv0964c-
Rv0965c 
- 1076689 A -> C - - 0.0 75.0 0.0 0.0 0.0 0.0 0.0 rs157705991 x x 
Rv0965c - 1076880 C -> T Synonymous A106A 0.0 89.8 0.0 0.0 0.0 0.0 0.0 rs157706002 x x 
Rv0965c - 1077102 C -> T Synonymous A32A 0.0 0.0 0.0 0.0 100.0 0.0 0.0 
rs157706012; 
rs157727994 
x x 
Rv0965c - 1077106 C -> A Nonsynonymous R31L 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Intergenic_Rv0965c-
Rv0966c 
- 1077211 C -> T -  0.0 0.0 0.0 0.0 0.0 13.3 0.0    
Rv0966c - 1077280 A -> C Nonsynonymous W186G 0.0 0.0 0.0 0.0 100.0 100.0 0.0 
rs157706020; 
rs157728002 
x x 
Rv0966c - 1077312 G -> A Nonsynonymous A175V 0.0 0.0 0.0 1.1 0.0 0.0 0.0 rs157706021 x x 
Rv0966c - 1077365 G -> A Synonymous H157H 6.3 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0966c - 1077521 C -> T Synonymous P105P 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0966c - 1077713 C -> T Synonymous Q41Q 0.0 0.0 0.0 0.0 0.0 0.0 100.0   x 
Rv0966c - 1077754 C -> T Nonsynonymous A28T 100.0 0.0 0.0 0.0 0.0 0.0 0.0 rs157706026 x x 
Intergenic_Rv0966c-
Rv0967c 
- 1077911 C -> T - - 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Intergenic_Rv0966c-
Rv0967c 
- 1077917 G -> A - - 0.0 0.0 0.0 0.0 0.0 41.2 0.0 rs157706031   
Intergenic_Rv0966c-
Rv0967c 
- 1077921 C -> T - - 0.0 0.0 0.0 1.1 0.0 5.9 0.0    
Rv0967 - 1077981 A -> G Nonsynonymous K3E 2.1 0.0 0.0 0.0 0.0 0.0 0.0 rs157706035 x x 
Rv0967 - 1078166 G -> A Synonymous T64T 0.0 2.0 0.0 0.0 0.0 0.0 0.0 rs157706036 x x 
Rv0968 - 1078398 G -> A Stogain W3X 17.5 0.0 0.0 0.0 0.0 0.0 0.0 rs157706037 x x 
Rv0969 ctpV 1078777 C -> A Nonsynonymous A12E 0.0 0.0 0.0 3.2 0.0 0.0 0.0    
Rv0969 ctpV 1079274 G -> A Nonsynonymous V178M 0.0 0.0 0.0 2.2 0.0 0.0 0.0    
Rv0969 ctpV 1079457 C -> T Nonsynonymous R239C 21.3 0.0 0.0 0.0 0.0 0.0 0.0 rs15770648 x x 
Rv0969 ctpV 1079473 G -> A Nonsynonymous R244K 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0969 ctpV 1079558 G -> C Nonsynonymous E272D 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0969 ctpV 1079830 G -> T Nonsynonymous G363V 0.0 0.0 0.0 0.0 5.9 0.0 0.0    
Rv0969 ctpV 1079927 A -> C Synonymous T395T 2.1 0.0 0.0 7.5 0.0 0.0 0.0 rs157706050 x x 
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Rv0969 ctpV 1080013 C -> T Nonsynonymous T424I 0.0 8.2 0.0 0.0 0.0 0.0 0.0   x 
Rv0969 ctpV 1080191 T -> C Synonymous P483P 0.0 0.0 0.0 1.1 0.0 0.0 0.0 rs157731275  x 
Rv0969 ctpV 1080192 A -> G Nonsynonymous N484D 2.1 0.0 2.7 100.0 0.0 0.0 0.0 rs157706051 x x 
Rv0969 ctpV 1080290 A -> G Nonsynonymous I516M 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0969 ctpV 1080366 G -> A Nonsynonymous G542R 0.0 0.0 0.0 0.0 0.0 11.8 0.0    
Rv0969 ctpV 1080376 A -> C Nonsynonymous K545T 0.0 0.0 2.7 0.0 0.0 0.0 0.0    
Rv0969 ctpV 1080493 T -> C Nonsynonymous V584A 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0969 ctpV 1080528 G -> A Nonsynonymous A596T 0.0 0.0 0.0 9.7 0.0 0.0 0.0 rs157731276  x 
Rv0969 ctpV 1080542 T -> C Synonymous G600G 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0969 ctpV 1080914 C -> T Synonymous Y724Y 0.0 0.0 0.0 0.0 0.0 11.8 0.0    
Rv0970 - 1081062 A -> G Nonsynonymous D4G 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0970 - 1081200 C -> T Nonsynonymous A50V 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0970 - 1081601 T -> G Nonsynonymous S184A 0.0 2.0 0.0 0.0 0.0 0.0 0.0 
rs157706055; 
rs157728012 
x x 
Rv0970 - 1081681 C -> T Synonymous V210V 0.0 0.0 0.0 3.2 0.0 0.0 0.0 rs157728013 x x 
Rv0971c echA7 1081831 G -> A Synonymous L252L 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0971c echA7 1081882 A -> G Nonsynonymous S235P 0.0 0.0 0.0 0.0 0.0 0.0 100.0   x 
Rv0971c echA7 1082433 G -> A Nonsynonymous A51V 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0971c echA7 1082445 T -> A Nonsynonymous E47V 0.0 0.0 0.0 9.7 0.0 0.0 0.0   x 
Rv0971c echA7 1082578 T -> G Nonsynonymous S3R 0.0 0.0 2.6 0.0 0.0 0.0 0.0    
Rv0972c fadE12 1082891 A -> C Nonsynonymous L287W 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0972c fadE12 1082983 G -> A Synonymous G256G 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0972c fadE12 1083179 G -> A Nonsynonymous T191I 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0972c fadE12 1083576 G -> T Nonsynonymous P59T 0.0 0.0 0.0 5.3 0.0 0.0 0.0    
Rv0972c fadE12 1083684 C -> T Nonsynonymous V23M 0.0 0.0 0.0 0.0 0.0 5.9 0.0    
Rv0973c accA2 1083755 A -> G Nonsynonymous S666P 100.0 0.0 0.0 0.0 0.0 0.0 0.0 rs157706062 x x 
Rv0973c accA2 1083944 C -> T Nonsynonymous E603K 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0973c accA2 1084048 G -> C Nonsynonymous P568R 0.0 0.0 5.0 0.0 0.0 0.0 0.0    
Rv0973c accA2 1084091 C -> A Nonsynonymous A554S 0.0 4.2 0.0 0.0 0.0 0.0 0.0   x 
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Rv0973c accA2 1084239 A -> G Synonymous R504R 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0973c accA2 1084280 A -> G Nonsynonymous W491R 0.0 0.0 5.0 0.0 0.0 0.0 0.0    
Rv0973c accA2 1084409 C -> G Nonsynonymous G448R 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0973c accA2 1084476 C -> T Synonymous L425L 0.0 0.0 0.0 1.1 0.0 0.0 0.0 rs157706065 x x 
Rv0973c accA2 1084567 T -> C Nonsynonymous Y395C 0.0 0.0 5.0 0.0 0.0 0.0 0.0    
Rv0973c accA2 1084812 G -> A Synonymous C313C 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0973c accA2 1084831 T -> C Nonsynonymous Q307R 0.0 2.1 0.0 0.0 0.0 0.0 0.0 rs157706066 x x 
Rv0973c accA2 1084863 T -> C Synonymous E296E 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0973c accA2 1084911 G -> A Synonymous Y280Y 0.0 0.0 15.0 0.0 0.0 0.0 0.0 rs157706067 x x 
Rv0973c accA2 1084967 C -> T Nonsynonymous A262T 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0973c accA2 1085489 C -> A Stogain E88X 0.0 2.1 0.0 0.0 0.0 0.0 0.0    
Rv0973c accA2 1085516 C -> T Nonsynonymous G79S 0.0 0.0 0.0 2.1 0.0 0.0 0.0    
Rv0974c accD2 1085919 C -> T Nonsynonymous G476D 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0974c accD2 1085983 C -> A Nonsynonymous A455S 0.0 0.0 0.0 0.0 0.0 11.8 0.0    
Rv0974c accD2 1086076 G -> C Nonsynonymous P424A 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0974c accD2 1086367 G -> A Nonsynonymous H327Y 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0974c accD2 1086525 G -> T Nonsynonymous P274Q 0.0 0.0 0.0 4.3 0.0 0.0 0.0 rs157706073 x x 
Rv0974c accD2 1086635 C -> A Nonsynonymous L237F 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0974c accD2 1086648 C -> A Nonsynonymous R233L 100.0 0.0 0.0 0.0 0.0 0.0 0.0 rs157706074 x x 
Rv0974c accD2 1086687 G -> A Nonsynonymous S220F 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0974c accD2 1086778 C -> T Nonsynonymous G190S 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0974c accD2 1086896 T -> A Nonsynonymous K150N 0.0 0.0 0.0 0.0 0.0 5.9 0.0    
Rv0974c accD2 1086902 G -> T Synonymous T148T 0.0 0.0 0.0 0.0 0.0 11.8 0.0    
Rv0974c accD2 1087193 C -> G Nonsynonymous K51N 2.1 0.0 2.5 18.1 0.0 0.0 0.0 rs157706078 x x 
Rv0974c accD2 1087210 G -> T Nonsynonymous H46N 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0974c accD2 1087279 T -> C Nonsynonymous K23E 0.0 0.0 0.0 11.7 0.0 0.0 0.0 
rs157731280; 
rs157733291 
 x 
Rv0975c fadE13 1087478 C -> T Nonsynonymous G340D 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0975c fadE13 1087534 C -> A Nonsynonymous K321N 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
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Rv0975c fadE13 1087699 C -> A Synonymous R266R 0.0 0.0 0.0 2.1 0.0 0.0 0.0   x 
Rv0975c fadE13 1087760 A -> G Nonsynonymous L246P 0.0 0.0 0.0 0.0 11.8 0.0 0.0 rs157706079 x x 
Rv0975c fadE13 1087812 T -> G Nonsynonymous N229H 0.0 0.0 0.0 2.1 0.0 0.0 0.0 rs157731281  x 
Rv0975c fadE13 1087824 C -> A Nonsynonymous V225L 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0975c fadE13 1087852 G -> A Synonymous T215T 16.7 0.0 0.0 0.0 0.0 0.0 0.0   x 
Rv0975c fadE13 1088097 C -> T Nonsynonymous D134N 0.0 0.0 0.0 0.0 11.8 0.0 0.0 rs157706080 x x 
Rv0975c fadE13 1088159 C -> T Nonsynonymous R113Q 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0975c fadE13 1088189 C -> T Nonsynonymous G103D 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0976c - 1088514 C -> T Synonymous E554E 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0976c - 1088600 T -> C Nonsynonymous I526V 0.0 2.0 2.5 0.0 0.0 0.0 0.0    
Rv0976c - 1088676 C -> T Synonymous L500L 0.0 0.0 0.0 3.2 0.0 0.0 0.0    
Rv0976c - 1088909 G -> A Nonsynonymous R423C 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0976c - 1089078 G -> A Synonymous A366A 0.0 0.0 5.0 0.0 0.0 0.0 0.0    
Rv0976c - 1089421 C -> T Nonsynonymous R252Q 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0976c - 1089554 T -> C Nonsynonymous T208A 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0976c - 1089922 G -> T Nonsynonymous P85H 0.0 0.0 0.0 1.1 0.0 0.0 0.0 
rs157731282; 
rs157733292 
 x 
Rv0976c - 1090077 G -> A Synonymous Y33Y 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0976c - 1090133 A -> G Nonsynonymous S15P 0.0 0.0 0.0 0.0 0.0 41.2 0.0    
Intergenic_Rv0979c-
Rv0979A 
- 1094885 C -> T - - 0.0 0.0 0.0 1.1 0.0 0.0 0.0 rs157731290  x 
Rv0979A rpmF 1095053 G -> T Nonsynonymous K56N 0.0 0.0 0.0 0.0 0.0 100.0 0.0 rs157706106 x x 
Rv0981 mprA 1096905 A -> C Nonsynonymous E28D 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0981 mprA 1097023 G -> A Nonsynonymous G68S 0.0 100.0 100.0 100.0 0.0 0.0 0.0 rs157706114 x x 
Rv0981 mprA 1097220 C -> T Synonymous S133S 0.0 100.0 100.0 0.0 0.0 0.0 0.0 rs157706115 x x 
Rv0981 mprA 1097328 G -> C Synonymous R169R 4.2 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0981 mprA 1097442 C -> T Synonymous D207D 0.0 89.8 0.0 0.0 0.0 0.0 0.0 rs157706116 x x 
Rv0982 mprB 1097633 C -> T Synonymous A42A 0.0 0.0 0.0 0.0 100.0 0.0 0.0 rs157706117 x x 
Rv0982 mprB 1097894 C -> T Synonymous T129T 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0982 mprB 1098141 C -> T Nonsynonymous P212S 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
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Rv0982 mprB 1098263 T -> C Synonymous R252R 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0982 mprB 1098266 C -> T Synonymous T253T 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0982 mprB 1098459 G -> A Nonsynonymous V318I 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0982 mprB 1098523 A -> T Nonsynonymous H339L 0.0 0.0 0.0 100.0 0.0 0.0 0.0 rs1577016118 x x 
Rv0982 mprB 1098698 C -> G Synonymous G397G 0.0 0.0 0.0 5.3 0.0 0.0 0.0   x 
Rv0982 mprB 1098710 C -> A Synonymous P401P 0.0 0.0 5.0 0.0 0.0 0.0 0.0    
Rv0982 mprB 1098711 G -> A Nonsynonymous V402M 0.0 0.0 0.0 0.0 0.0 5.9 0.0    
Rv0982 mprB 1098984 G -> A Nonsynonymous V493I 0.0 0.0 7.5 0.0 0.0 0.0 0.0 rs157706119 x x 
Intergenic_Rv0982-
Rv0983 
- 1099058 G -> A - - 0.0 100.0 100.0 0.0 0.0 0.0 0.0 rs157706120 x x 
Rv0983 pepD 1099092 C -> T Synonymous G9G 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0983 pepD 1099212 C -> T Synonymous F49F 18.8 0.0 0.0 0.0 0.0 0.0 0.0 rs157706122 x x 
Rv0983 pepD 1099237 C -> A Nonsynonymous P58T 0.0 0.0 0.0 0.0 0.0 11.8 0.0    
Rv0983 pepD 1099573 T -> C Synonymous L170L 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0983 pepD 1099678 C -> A Nonsynonymous P205T 0.0 2.0 0.0 0.0 0.0 0.0 0.0 rs157706125   
Rv0983 pepD 1099797 C -> A Synonymous G244G 0.0 8.2 0.0 0.0 0.0 0.0 0.0   x 
Rv0983 pepD 1100234 C -> T Nonsynonymous P390L 0.0 0.0 0.0 3.2 0.0 0.0 0.0 rs157706128 x x 
Rv0983 pepD 1100414 G -> A Nonsynonymous G450D 0.0 0.0 27.5 0.0 0.0 0.0 0.0 rs157735240  x 
Rv0984 moaB2 1100589 C -> T Nonsynonymous H44Y 4.2 0.0 0.0 0.0 0.0 0.0 0.0 rs157706130 x x 
Rv0985c mscL 1101092 C -> T Nonsynonymous G130E 0.0 0.0 0.0 4.3 0.0 0.0 0.0 rs157706132 x x 
Rv0985c mscL 1101174 C -> T Nonsynonymous V103I 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0985c mscL 1101179 C -> T Nonsynonymous G101E 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0985c mscL 1101317 C -> G Nonsynonymous G55A 0.0 4.2 0.0 0.0 0.0 0.0 0.0    
Rv0985c mscL 1101353 A -> C Nonsynonymous I43S 0.0 0.0 0.0 2.1 0.0 0.0 0.0   x 
Intergenic_Rv0985c-
Rv0986 
- 1101516 G -> T - - 2.1 0.0 0.0 0.0 0.0 0.0 0.0 rs157706135 x x 
Intergenic_Rv0985c-
Rv0986 
- 1101578 C -> G - - 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0986 - 1101814 A -> C Nonsynonymous Q4H 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0986 - 1102117 G -> A Synonymous V105V 0.0 89.8 0.0 0.0 0.0 0.0 0.0 rs157706139 x x 
Rv0986 - 1102175 G -> A Nonsynonymous V125M 0.0 0.0 0.0 0.0 0.0 11.8 0.0    
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Rv0986 - 1102273 T -> G Nonsynonymous I157M 0.0 0.0 0.0 0.0 0.0 0.0 100.0   x 
Rv0986 - 1102468 C -> A Synonymous G222G 0.0 100.0 0.0 0.0 0.0 0.0 0.0 rs157706141 x x 
Rv0986 - 1102484 G -> T Nonsynonymous V228L 0.0 0.0 0.0 0.0 100.0 100.0 0.0 rs157706142 x x 
Rv0986 - 1102520 A -> G Nonsynonymous T240A 0.0 0.0 2.5 1.1 0.0 0.0 0.0    
Rv0987 - 1102646 G -> A Synonymous A35A 0.0 89.8 0.0 0.0 0.0 0.0 0.0 rs157706143 x x 
Rv0987 - 1102788 G -> T Nonsynonymous V83F 0.0 0.0 0.0 7.4 0.0 0.0 0.0 rs157731291  x 
Rv0987 - 1102805 C -> T Synonymous H88H 0.0 0.0 0.0 0.0 0.0 17.6 0.0    
Rv0987 - 1102924 T -> C Nonsynonymous L128S 4.2 0.0 0.0 0.0 0.0 0.0 0.0   x 
Rv0987 - 1102973 C -> G Synonymous P144P 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0987 - 1103046 G -> C Nonsynonymous V169L 10.4 8.2 0.0 0.0 0.0 0.0 0.0   x 
Rv0987 - 1103126 C -> A Nonsynonymous D195E 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0987 - 1103206 A -> C Nonsynonymous K222T 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0987 - 1103249 C -> T Synonymous A236A 0.0 0.0 0.0 21.3 0.0 0.0 0.0 rs157706148 x x 
Rv0987 - 1103289 G -> C Nonsynonymous V250L 0.0 0.0 0.0 0.0 5.9 0.0 0.0    
Rv0987 - 1103487 G -> A Nonsynonymous G316R 12.5 0.0 0.0 0.0 0.0 0.0 0.0 
rs157706151; 
rs157728037 
x x 
Rv0987 - 1103656 C -> T Nonsynonymous A372V 0.0 73.5 0.0 0.0 0.0 0.0 0.0 rs157706152 x x 
Rv0987 - 1103786 G -> T Nonsynonymous L415F 0.0 0.0 0.0 12.8 0.0 0.0 0.0    
Rv0987 - 1103908 T -> C Nonsynonymous M456T 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0987 - 1103955 C -> T Stogain R472X 0.0 2.0 0.0 0.0 0.0 0.0 0.0 rs157706153 x x 
Rv0987 - 1103995 C -> T Nonsynonymous T485I 22.9 0.0 0.0 0.0 0.0 0.0 0.0 rs157706154 x x 
Rv0987 - 1104044 C -> T Synonymous G501G 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0987 - 1104140 A -> G Synonymous T533T 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0987 - 1104308 A -> G Synonymous R589R 0.0 0.0 0.0 2.1 0.0 0.0 0.0    
Rv0987 - 1104499 A -> G Nonsynonymous D653G 0.0 0.0 0.0 0.0 100.0 0.0 0.0 rs157706158 x x 
Rv0987 - 1104518 G -> A Nonsynonymous M659I 0.0 4.1 0.0 0.0 0.0 0.0 0.0    
Rv0987 - 1104626 C -> G Synonymous A695A 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0987 - 1104634 C -> T Nonsynonymous A698V 16.7 0.0 0.0 0.0 0.0 0.0 0.0 rs157706160 x x 
Rv0987 - 1104654 A -> G Nonsynonymous I705V 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
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Rv0987 - 1104690 G -> T Nonsynonymous V717F 0.0 0.0 0.0 100.0 0.0 0.0 0.0 rs157706161 x x 
Rv0987 - 1104740 C -> A Synonymous A733A 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0987 - 1104928 C -> T Nonsynonymous A796V 16.7 0.0 0.0 0.0 0.0 0.0 0.0   x 
Rv0987 - 1104944 C -> T Synonymous R801R 0.0 8.2 0.0 0.0 0.0 0.0 0.0   x 
Rv0987 - 1104956 C -> T Synonymous V805V 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0987 - 1104967 G -> A Nonsynonymous G809D 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0987 - 1104996 G -> C Nonsynonymous A819P 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0987 - 1105056 C -> T Nonsynonymous P839S 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0987 - 1105102 A -> C Nonsynonymous E854A 0.0 0.0 0.0 12.8 0.0 0.0 0.0   x 
Intergenic_Rv0987-
Rv0988 
- 1105111 G -> T - - 0.0 0.0 0.0 1.1 0.0 0.0 0.0   x 
Rv0988 - 1105216 A -> G Nonsynonymous D34G 0.0 0.0 0.0 0.0 5.9 0.0 0.0    
Rv0988 - 1105284 A -> G Nonsynonymous V57I 0.0 100.0 100.0 100.0 0.0 0.0 0.0 rs157706165 x x 
Rv0988 - 1105342 A -> G Nonsynonymous Y76C 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0988 - 1105346 C -> A Synonymous T77T 0.0 8.3 0.0 0.0 0.0 0.0 0.0 rs157706166 x x 
Rv0988 - 1105367 C -> T Synonymous D84D 8.3 0.0 0.0 0.0 0.0 0.0 0.0   x 
Rv0988 - 1105424 C -> T Synonymous G103G 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0988 - 1105505 G -> T Synonymous S130S 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0988 - 1105525 C -> T Nonsynonymous A137V 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0988 - 1105557 G -> T Nonsynonymous A148S 0.0 0.0 0.0 0.0 100.0 0.0 0.0 rs157706167 x x 
Rv0988 - 1105587 T -> C Nonsynonymous W158R 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0988 - 1105686 C -> G Nonsynonymous L191A 0.0 68.8 0.0 0.0 0.0 0.0 0.0 rs157706168 x x 
Rv0988 - 1105687 T -> C Nonsynonymous L191A 0.0 68.8 0.0 0.0 0.0 0.0 0.0 rs157706169 x x 
Rv0988 - 1105739 G -> C Synonymous P208P 0.0 0.0 0.0 0.0 0.0 0.0 100.0   x 
Rv0988 - 1105832 C -> G Nonsynonymous S239R 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0988 - 1105877 T -> C Synonymous D254D 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0988 - 1106099 C -> T Synonymous I328I 0.0 0.0 100.0 0.0 0.0 0.0 0.0 rs157706173 x x 
Rv0988 - 1106219 G -> T Nonsynonymous M368I 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Intergenic_Rv0988-
Rv0989c 
- 1106289 G -> T - - 0.0 0.0 0.0 2.1 0.0 0.0 0.0   x 
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Intergenic_Rv0988-
Rv0989c 
- 1106311 G -> A - - 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0989c grcC2 1106409 T -> C Nonsynonymous D325G 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0989c grcC2 1106422 C -> T Nonsynonymous V321I 0.0 0.0 0.0 17.9 0.0 0.0 0.0 rs157706176 x x 
Rv0989c grcC2 1106464 G -> A Nonsynonymous R307C 0.0 8.2 0.0 0.0 0.0 0.0 0.0   x 
Rv0989c grcC2 1106492 C -> T Synonymous A297A 0.0 0.0 5.0 0.0 0.0 0.0 0.0    
Rv0989c grcC2 1106598 G -> C Nonsynonymous A262G 0.0 0.0 0.0 0.0 0.0 23.5 0.0 
rs157706177; 
rs157728040 
x x 
Rv0989c grcC2 1106614 G -> T Nonsynonymous L257M 0.0 12.2 0.0 0.0 0.0 0.0 0.0 
rs157706178; 
rs157728041 
x x 
Rv0989c grcC2 1106652 A -> G Nonsynonymous L244P 0.0 0.0 0.0 9.5 0.0 0.0 0.0    
Rv0989c grcC2 1106838 G -> C Nonsynonymous A182G 0.0 10.2 0.0 0.0 0.0 0.0 0.0 rs157734969  x 
Rv0989c grcC2 1106842 T -> C Nonsynonymous I181V 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0989c grcC2 1106875 G -> C Nonsynonymous L170V 0.0 0.0 5.0 0.0 0.0 0.0 0.0    
Rv0989c grcC2 1106877 T -> C Nonsynonymous Y169C 0.0 0.0 0.0 7.4 0.0 0.0 0.0 rs157731295  x 
Rv0989c grcC2 1106959 C -> T Nonsynonymous A142T 0.0 0.0 0.0 2.1 0.0 0.0 0.0    
Rv0989c grcC2 1106961 A -> G Nonsynonymous V141A 0.0 0.0 2.5 0.0 0.0 0.0 0.0 rs157706180   
Rv0989c grcC2 1106962 C -> G Nonsynonymous V141L 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0989c grcC2 1107024 T -> C Nonsynonymous D120G 0.0 0.0 0.0 0.0 100.0 0.0 0.0 rs157706181 x x 
Rv0989c grcC2 1107077 C -> T Synonymous K102K 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0989c grcC2 1107134 C -> T Nonsynonymous M83I 4.2 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0989c grcC2 1107320 G -> A Synonymous A21A 0.0 0.0 0.0 0.0 5.9 0.0 0.0    
Intergenic_Rv0989c-
Rv0990c 
- 1107434 A -> T - - 0.0 0.0 0.0 20.0 0.0 0.0 0.0 rs157706182 x x 
Rv0990c - 1107897 G -> A Nonsynonymous A68V 0.0 0.0 0.0 0.0 0.0 100.0 0.0 
rs157706183; 
rs157728042 
x x 
Rv0990c - 1107917 G -> T Nonsynonymous H61Q 0.0 2.0 0.0 21.1 0.0 0.0 0.0 rs157706184 x x 
Rv0990c - 1107940 C -> A Nonsynonymous A54S 2.1 2.0 0.0 100.0 0.0 0.0 0.0 
rs157706185; 
rs157728043 
x x 
Rv0990c - 1107986 C -> T Nonsynonymous M38I 4.2 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0990c - 1108072 G -> A Synonymous L10L 0.0 0.0 0.0 0.0 5.9 0.0 0.0    
Rv0990c - 1108077 G -> A Nonsynonymous P8L 0.0 0.0 0.0 0.0 0.0 5.9 0.0    
Intergenic_Rv0990c-
Rv0991c 
- 1108113 G -> T - - 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
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Rv0991c - 1108199 G -> A Synonymous S102S 0.0 0.0 5.0 0.0 0.0 0.0 0.0    
Rv0991c - 1108325 G -> A Synonymous - 0.0 0.0 0.0 0.0 0.0 5.9 0.0    
Intergenic_Rv0991c-
Rv0992c 
- 1108521 G -> A - - 0.0 69.4 0.0 0.0 0.0 0.0 0.0 rs157706187 x x 
Rv0992c - 1108599 G -> C Nonsynonymous I191M 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0992c - 1108788 C -> T Synonymous A128A 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0992c - 1108939 C -> T Nonsynonymous R78H 2.1 0.0 0.0 0.0 0.0 0.0 0.0 rs157706188 x x 
Rv0992c - 1109163 G -> C Nonsynonymous I3M 0.0 100.0 100.0 100.0 0.0 0.0 0.0 rs157706189 x x 
Rv0993 galU 1109278 C -> T Nonsynonymous R3C 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0993 galU 1109296 C -> T Nonsynonymous P9S 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0993 galU 1109313 C -> G Synonymous V14V 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0993 galU 1109391 T -> G Synonymous T40T 0.0 0.0 0.0 0.0 58.8 0.0 0.0 rs157706190 x x 
Rv0993 galU 1109535 G -> A Synonymous K88K 0.0 0.0 0.0 2.1 0.0 0.0 0.0   x 
Rv0993 galU 1109975 G -> A Nonsynonymous R235Q 0.0 0.0 0.0 6.3 0.0 0.0 0.0 rs157706191 x x 
Rv0993 galU 1110177 T -> G Synonymous G302G 0.0 0.0 0.0 0.0 11.8 0.0 0.0 
rs157706192; 
rs157728045 
x x 
Intergenic_Rv0993-
Rv0994 
- 1110225 G -> A - - 0.0 0.0 0.0 0.0 0.0 5.9 0.0    
Rv0994 moeA1 1110295 T -> G Synonymous A9A 0.0 0.0 2.6 0.0 0.0 0.0 0.0    
Rv0994 moeA1 1110574 G -> T Nonsynonymous R102S 0.0 0.0 0.0 0.0 0.0 5.9 0.0 rs157706193   
Rv0994 moeA1 1110721 T -> C Synonymous R151R 0.0 0.0 69.2 0.0 0.0 0.0 0.0 rs157735264  x 
Rv0994 moeA1 1110750 T -> C Nonsynonymous V161A 6.3 0.0 0.0 0.0 0.0 0.0 0.0 rs157706194 x x 
Rv0994 moeA1 1110916 C -> A Nonsynonymous D216E 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0994 moeA1 1110956 G -> T Nonsynonymous G230C 0.0 100.0 100.0 100.0 0.0 0.0 0.0 rs157706195 x x 
Rv0994 moeA1 1111228 G -> A Synonymous L320L 14.6 0.0 0.0 0.0 0.0 0.0 0.0   x 
Rv0994 moeA1 1111382 G -> A Nonsynonymous D372N 0.0 0.0 0.0 0.0 5.9 0.0 0.0    
Rv0994 moeA1 1111397 C -> T Synonymous L377L 0.0 0.0 0.0 0.0 0.0 5.9 0.0 rs157706196 x x 
Rv0994 moeA1 1111448 A -> G Nonsynonymous T394A 0.0 8.2 0.0 0.0 0.0 0.0 0.0   x 
Rv0994 moeA1 1111462 G -> T Synonymous A398A 0.0 0.0 2.6 0.0 0.0 0.0 0.0    
Rv0994 moeA1 1111469 C -> T Synonymous L401L 14.6 0.0 0.0 0.0 0.0 0.0 0.0 rs157706197 x x 
Rv0994 moeA1 1111518 T -> C Nonsynonymous V417A 97.9 0.0 0.0 0.0 0.0 0.0 0.0 rs1577061698 x x 
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Rv0994 moeA1 1111528 C -> T Synonymous A420A 4.2 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0995 rimJ 1111678 G -> A Nonsynonymous G23S 0.0 69.4 0.0 0.0 0.0 0.0 0.0 
rs157706199; 
rs157733669 
x x 
Rv0995 rimJ 1111784 C -> T Nonsynonymous P58L 0.0 0.0 0.0 2.1 0.0 0.0 0.0 
rs157731297; 
rs157733670 
  
Rv0995 rimJ 1111826 G -> T Nonsynonymous R72L 0.0 0.0 0.0 10.5 0.0 0.0 0.0 
rs157731298; 
rs157733671 
 x 
Rv0995 rimJ 1111852 G -> T Nonsynonymous D81Y 0.0 0.0 100.0 0.0 0.0 0.0 0.0 rs157706200 x x 
Rv0995 rimJ 1111921 G -> A Nonsynonymous G104S 0.0 2.0 0.0 0.0 0.0 0.0 0.0 rs157706201 x x 
Rv0995 rimJ 1111925 A -> G Nonsynonymous Y105C 0.0 0.0 0.0 10.5 0.0 0.0 0.0 
rs157731299; 
rs157733672 
 x 
Rv0995 rimJ 1111993 T -> G Nonsynonymous C128G 6.3 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0995 rimJ 1112027 C -> T Nonsynonymous A139V 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Intergenic_Rv0995-
Rv0996 
- 1112226 C -> A - - 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Intergenic_Rv0995-
Rv0996 
- 1112327 C -> A - - 0.0 0.0 0.0 0.0 0.0 0.0 25.0    
Intergenic_Rv0995-
Rv0996 
- 1112333 T -> A - - 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0996 - 1112530 T -> C Synonymous A49A 0.0 0.0 0.0 1.1 0.0 0.0 0.0 rs157706202 x x 
Rv0996 - 1112630 G -> C Nonsynonymous E83Q 0.0 0.0 0.0 0.0 5.9 0.0 0.0    
Rv0996 - 1112752 G -> A Synonymous P123P 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0996 - 1112880 C -> T Nonsynonymous A166V 8.3 0.0 0.0 0.0 0.0 0.0 0.0   x 
Rv0996 - 1113029 C -> A Nonsynonymous R216S 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0996 - 1113226 C -> G Synonymous T281T 0.0 0.0 0.0 1.1 0.0 0.0 0.0 rs157731301   
Rv0996 - 1113290 C -> G Nonsynonymous Q303E 0.0 100.0 100.0 100.0 0.0 0.0 0.0 rs157706205 x x 
Rv0996 - 1113292 G -> C Nonsynonymous Q303H 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0996 - 1113326 T -> C Nonsynonymous S315P 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0996 - 1113403 G -> A Synonymous A340A 12.5 0.0 0.0 0.0 0.0 0.0 0.0 rs157706207 x x 
Intergenic_Rv0996-
Rv0997 
- 1113733 C -> A - - 0.0 0.0 70.0 0.0 0.0 0.0 0.0 rs157706209 x x 
Intergenic_Rv0996-
Rv0997 
- 1113750 C -> T - - 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Intergenic_Rv0996-
Rv0997 
- 1113783 C -> T - - 4.2 0.0 0.0 0.0 0.0 0.0 0.0    
Intergenic_Rv0996-
Rv0997 
- 1113840 A -> G - - 0.0 0.0 0.0 2.1 0.0 0.0 0.0 rs157706210 x x 
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Intergenic_Rv0996-
Rv0997 
- 1114129 T -> G - - 0.0 0.0 0.0 0.0 100.0 0.0 0.0 rs157706211 x x 
Intergenic_Rv0996-
Rv0997 
- 1114261 G -> C - - 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Intergenic_Rv0996-
Rv0997 
- 1114289 G -> A - - 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0997 - 1114361 C -> T Synonymous G23G 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv0997 - 1114494 G -> A Nonsynonymous G68S 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0997 - 1114503 C -> T Stogain Q71X 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0997 - 1114539 A -> C Nonsynonymous T83P 0.0 2.0 0.0 0.0 0.0 0.0 0.0    
Rv0998 - 1114860 C -> G Nonsynonymous P38R 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0998 - 1114981 C -> T Synonymous I78I 0.0 0.0 0.0 0.0 5.9 0.0 0.0    
Rv0998 - 1115075 G -> A Nonsynonymous G110S 0.0 0.0 0.0 0.0 0.0 29.4 0.0    
Rv0998 - 1115198 G -> T Nonsynonymous A151S 2.1 2.0 2.5 0.0 0.0 0.0 0.0    
Rv0998 - 1115509 C -> T Synonymous I254I 0.0 0.0 27.5 0.0 0.0 0.0 0.0 rs157735268  x 
Rv0999 - 1115796 C -> A Synonymous A10A 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv0999 - 1115857 T -> G Nonsynonymous L31V 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv0999 - 1115880 A -> C Synonymous V38V 0.0 0.0 15.0 0.0 0.0 0.0 0.0 rs157706216   
Rv0999 - 1115884 G -> A Nonsynonymous A40T 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv1000c - 1116592 T -> G Nonsynonymous K186T 0.0 0.0 0.0 2.1 0.0 0.0 0.0   x 
Rv1000c - 1116838 T -> A Nonsynonymous E104V 2.1 0.0 0.0 0.0 0.0 0.0 0.0    
Rv1001 arcA 1117308 C -> T Synonymous L42L 0.0 0.0 0.0 0.0 0.0 100.0 0.0 rs157706220 x x 
Rv1001 arcA 1117405 C -> T Nonsynonymous T74I 97.9 0.0 0.0 0.0 0.0 0.0 0.0 rs157706221 x x 
Rv1001 arcA 1117568 C -> T Synonymous N128N 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv1001 arcA 1117656 C -> T Synonymous L158L 0.0 0.0 0.0 0.0 5.9 0.0 0.0    
Rv1001 arcA 1117758 A -> G Nonsynonymous I192V 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
Rv1001 arcA 1117773 C -> G Nonsynonymous P197A 0.0 0.0 0.0 3.2 0.0 0.0 0.0   x 
Rv1001 arcA 1117990 T -> G Nonsynonymous L269R 0.0 0.0 2.5 0.0 0.0 0.0 0.0    
Rv1001 arcA 1118006 G -> C Synonymous T274T 0.0 0.0 0.0 3.2 0.0 0.0 0.0 
rs157731303; 
rs157733297 
 x 
Rv1001 arcA 1118020 A -> G Nonsynonymous D279G 0.0 0.0 0.0 1.1 0.0 0.0 0.0 
rs157706223; 
rs157728046 
x x 
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Rv1001 arcA 1118270 A -> G Synonymous V362V 0.0 0.0 0.0 0.0 0.0 100.0 0.0 
rs157706228; 
rs157728050 
x x 
Rv1001 arcA 1118293 A -> G Nonsynonymous D370G 0.0 0.0 0.0 1.1 0.0 0.0 0.0    
 
aSherry ST, Ward M-H, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29: 308–311. doi:10.1093/nar/29.1.308 
bReddy TBK, Riley R, Wymore F, Montgomery P, Decaprio D, Engels R, et al. TB database: An integrated platform for tuberculosis research. Nucleic Acids Res. 2009;37: 499–508. doi:10.1093/nar/gkn652 
cJoshi KR, Dhiman H, Scaria V. tbvar: A comprehensive genome variation resource for Mycobacterium tuberculosis. Database (Oxford). England; 2014;2014: bat083. doi:10.1093/database/bat083
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HLA alleles used in the immunoinformatics analysis 
 
Supplementary Table 2. HLA class I and class II alleles used in the T cell epitope prediction.  
  
HLA  class I 
HLA-A*01:01, HLA-A*02:01, HLA-A*02:02, HLA-A*02:03, 
HLA-A*02:06, HLA-A*02:07, HLA-A*02:22, HLA-A*03:01, 
HLA-A*11:01, HLA-A*23:01, HLA-A*24:02, HLA-A*24:07, 
HLA-A*24:20, HLA-A*26:01, HLA-A*29:02, HLA-A*30:01, 
HLA-A*31:01, HLA-A*31:08, HLA-A*32:01, HLA-A*33:01, 
HLA-A*33:03, HLA-A*34:01, HLA-A*68:01, HLA-A*74:01, 
HLA-B*07:02, HLA-B*07:05, HLA-B*08:01, HLA-B*13:01, 
HLA-B*13:02, HLA-B*14:01, HLA-B*14:02, HLA-B*14:05, 
HLA-B*15:01, HLA-B*15:02, HLA-B*15:03, HLA-B*15:04, 
HLA-B*15:07, HLA-B*15:10, HLA-B*15:11, HLA-B*15:13, 
HLA-B*15:21, HLA-B*15:32, HLA-B*18:01, HLA-B*18:02, 
HLA-B*27:04, HLA-B*27:05, HLA-B*35:01, HLA-B*35:03, 
HLA-B*35:05, HLA-B*35:06, HLA-B*39:01, HLA-B*39:06, 
HLA-B*40:01, HLA-B*40:02, HLA-B*40:06, HLA-B*42:01, 
HLA-B*44:03, HLA-B*44:04, HLA-B*44:06, HLA-B*45:01, 
HLA-B*46:01, HLA-B*48:01, HLA-B*48:03, HLA-B*51:01, 
HLA-B*52:01, HLA-B*53:01, HLA-B*53:03, HLA-B*55:02, 
HLA-B*56:01, HLA-B*57:01, HLA-B*58:01, HLA-B*58:02 
HLA  class II 
DRB1*01:01, DRB1*01:02, DRB1*03:01, DRB1*03:02, 
DRB1*04:01, DRB1*04:02, DRB1*04:03, DRB1*04:04, 
DRB1*04:05, DRB1*04:07, DRB1*04:11, DRB1*07:01, 
DRB1*08:01, DRB1*08:02, DRB1*08:03, DRB1*08:04, 
DRB1*08:07, DRB1*09:01, DRB1*10:01, DRB1*11:01, 
DRB1*11:02, DRB1*11:03, DRB1*11:04, DRB1*12:01, 
DRB1*12:02, DRB1*13:01, DRB1*13:02, DRB1*13:03, 
DRB1*13:04, DRB1*14:01, DRB1*14:02, DRB1*14:03, 
DRB1*14:04, DRB1*14:05, DRB1*14:13, DRB1*15:01, 
DRB1*15:02, DRB1*15:03, DRB1*15:04, DRB1*16:01, 
DRB1*16:02 
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Calculation of the normalized percentage of high binding affinity peptides 
 
Supplementary Figure 1. Example of the calculation of the normalized percentage of predicted peptides with high binding 
affinity to HLA molecules. 
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Geographic regions used for the estimation of the regional population 
coverage and MTBC lineages distribution 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2. Geographic regions used for the estimation of the regional population coverage and MTBC lineages 
distribution. The world map was divided in 15 geographic regions (in different colors), according to the population coverage tool 
(http://tools.iedb.org/tools/population/iedb_input) of The Allele Frequency Net Database [133]. The distribution of the countries was further 
complemented on the basis of the United Nations guidelines (http://unstats.un.org/unsd/methods/m49/m49regin.htm). Northeast Asia and 
East Asia were grouped into Eastern Asia. a No datasets of HLA frequencies were available for Central Asia at the time of the analysis. 
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HLA alleles with predicted high binding affinity peptides encompassing wild-type and variant amino acid residues under 
diversifying selection  
 
Supplementary Table 3. HLA alleles with predicted high binding affinity peptides encompassing wild-type and variant amino acid residues under diversifying selection. 
Amino acid 
substitution 
HLA class I HLA class II 
Wild-type Variant Wild-type Variant 
Number Type Number Type Number Type Number Type 
LprP 
L186P 
29 
HLA-A*24:02, HLA-A*24:07, 
HLA-A*24:20, HLA-A*31:01, 
HLA-A*31:08, HLA-A*33:03, 
HLA-A*68:01, HLA-B*07:02, 
HLA-B*07:05, HLA-B*15:03, 
HLA-B*15:04, HLA-B*15:10, 
HLA-B*15:13, HLA-B*35:01, 
HLA-B*35:03, HLA-B*35:05, 
HLA-B*35:06, HLA-B*39:01, 
HLA-B*39:03, HLA-B*42:01, 
HLA-B*44:06, HLA-B*46:01, 
HLA-B*51:01, HLA-B*53:01, 
HLA-B*53:03, HLA-B*55:02, 
HLA-B*56:01, HLA-B*57:01, 
HLA-B*58:01, HLA-B*58:02 
17 
HLA-B*07:02, HLA-B*07:05, 
HLA-B*35:03, HLA-B*35:06, 
HLA-A*31:01, HLA-A*31:08, 
HLA-A*33:03, HLA-A*68:01, 
HLA-B*15:03, HLA-B*15:10, 
HLA-B*15:13, HLA-B*44:06, 
HLA-B*46:01, HLA-B*53:01, 
HLA-B*57:01, HLA-B*58:01, 
HLA-B*58:02 
3 
DRB1*01:01, DRB1*01:02, 
DRB1*14:13 
2 DRB1*01:01, DRB1*01:02 
AccA2 
S666P 
0 - 0 - 0 - 0 - 
AccD2 
K51N 
3 
HLA-A*31:01, HLA-A*33:01, 
HLA-A*33:03 
4 
HLA-A*31:01, HLA-A*33:01, 
HLA-A*33:03, HLA-B*15:10 
0 - 0 - 
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AccD2 
R233L 
29 
HLA-A*26:01, HLA-A*30:01, 
HLA-A*30:02, HLA-A*68:01, 
HLA-B*07:02, HLA-B*07:05, 
HLA-B*08:01, HLA-B*13:01, 
HLA-B*14:02, HLA-B*14:05, 
HLA-B*15:02, HLA-B*15:03, 
HLA-B*15:04, HLA-B*15:10, 
HLA-B*15:11, HLA-B*15:13, 
HLA-B*15:21, HLA-B*18:01, 
HLA-B*39:01, HLA-B*39:03, 
HLA-B*39:06, HLA-B*40:01, 
HLA-B*40:02, HLA-B*40:06, 
HLA-B*44:03, HLA-B*44:04, 
HLA-B*45:01, HLA-B*48:01, 
HLA-B*48:03 
36 
HLA-A*01:01,HLA-
A*02:01,HLA-A*02:03,HLA-
A*02:06,HLA-A*02:07,HLA-
A*02:22,HLA-A*29:02,HLA-
A*30:02,HLA-B*13:01,HLA-
B*15:04,HLA-B*15:10,HLA-
B*18:01,HLA-B*35:01,HLA-
B*35:03,HLA-B*35:05,HLA-
B*35:06,HLA-B*39:01,HLA-
B*39:03,HLA-B*39:06,HLA-
B*44:03,HLA-B*44:04,HLA-
B*45:01,HLA-B*53:03,HLA-
A*26:01,HLA-B*14:02,HLA-
B*14:05,HLA-B*15:02,HLA-
B*15:03,HLA-B*15:11,HLA-
B*15:13,HLA-B*15:21,HLA-
B*40:01,HLA-B*40:02,HLA-
B*40:06,HLA-B*48:01,HLA-
B*48:03 
2 DRB1*01:01, DRB1*01:02 5 
DRB1*01:01, DRB1*01:02, 
DRB1*12:01, DRB1*12:02, 
DRB1*14:13 
Rv0987 
V169L 
8 
HLA-A*02:03,HLA-
A*02:06,HLA-A*02:22,HLA-
B*13:01,HLA-B*13:02,HLA-
B*15:03,HLA-B*48:01,HLA-
B*48:03 
9 
HLA-A*02:03,HLA-
A*02:06,HLA-A*02:22,HLA-
A*24:07,HLA-B*13:01,HLA-
B*13:02,HLA-B*15:03,HLA-
B*48:01,HLA-B*48:03 
6 
DRB1*01:01, DRB1*01:02, 
DRB1*07:01, DRB1*13:03, 
DRB1*13:04, DRB1*14:13 
9 
DRB1*01:01, DRB1*01:02, 
DRB1*07:01, DRB1*11:04, 
DRB1*12:01, DRB1*12:02, 
DRB1*13:03, DRB1*13:04, 
DRB1*14:13 
Rv0988 
L191A 
10 
HLA-A*02:01, HLA-A*02:03, 
HLA-A*02:06, HLA-A*02:22, 
HLA-B*13:02, HLA-B*48:01, 
HLA-B*48:03, HLA-B*51:01, 
HLA-B*52:01, HLA-B*56:01 
5 
HLA-A*02:06, HLA-B*13:02, 
HLA-B*48:01, HLA-B*48:03, 
HLA-B*52:01 
9 
DRB1*01:01, DRB1*01:02, 
DRB1*07:01, DRB1*11:04, 
DRB1*12:01, DRB1*12:02, 
DRB1*13:03, DRB1*13:04, 
DRB1*14:13 
6 
DRB1*01:01, DRB1*01:02, 
DRB1*07:01, DRB1*13:03, 
DRB1*13:04, DRB1*14:13 
GrcC2 
V141L 
22 
HLA-A*02:01, HLA-A*02:03, 
HLA-A*02:06, HLA-A*02:22, 
HLA-A*26:01, HLA-A*34:01, 
HLA-A*68:02, HLA-B*15:02, 
HLA-B*15:03, HLA-B*15:11, 
HLA-B*15:13, HLA-B*15:21, 
HLA-B*35:01, HLA-B*35:03, 
HLA-B*35:05, HLA-B*35:06, 
25 
HLA-A*02:01, HLA-A*02:03, 
HLA-A*02:06, HLA-A*02:07, 
HLA-A*02:22, HLA-A*34:01, 
HLA-B*35:06, HLA-B*39:01, 
HLA-B*39:03, HLA-A*26:01, 
HLA-A*68:02, HLA-B*15:02, 
HLA-B*15:03, HLA-B*15:11, 
HLA-B*15:13, HLA-B*15:21, 
4 
DRB1*01:01, DRB1*01:02, 
DRB1*11:04, DRB1*14:13 
4 
DRB1*01:01, DRB1*01:02, 
DRB1*11:04, DRB1*14:13 
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HLA-B*44:06, HLA-B*46:01, 
HLA-B*51:01, HLA-B*52:01, 
HLA-B*53:01, HLA-B*53:03 
HLA-B*35:01, HLA-B*35:03, 
HLA-B*35:05, HLA-B*44:06, 
HLA-B*46:01, HLA-B*51:01, 
HLA-B*52:01, HLA-B*53:01, 
HLA-B*53:03 
Rv0990c 
A54S 
7 
HLA-A*02:03, HLA-B*39:01, 
HLA-B*39:06, HLA-B*40:01, 
HLA-B*40:02, HLA-B*44:03, 
HLA-B*44:04 
5 
HLA-A*02:03, HLA-B*39:01, 
HLA-B*40:01, HLA-B*44:03, 
HLA-B*44:04 
4 
DRB1*01:01, DRB1*01:02, 
DRB1*11:04, DRB1*14:13 
4 
DRB1*01:01, DRB1*01:02, 
DRB1*11:04, DRB1*14:13 
Rv0990c 
A68V 
4 
HLA-A*11:01, HLA-B*07:02, 
HLA-B*07:05, HLA-B*15:10 
5 
HLA-A*11:01, HLA-A*68:02, 
HLA-B*07:02, HLA-B*07:05, 
HLA-B*15:10 
0 - 1 DRB1*14:13 
RimJ D81Y 26 
HLA-A*23:01, HLA-A*26:01, 
HLA-A*31:08, HLA-A*32:01, 
HLA-A*34:01, HLA-B*13:01, 
HLA-B*13:02, HLA-B*15:01, 
HLA-B*15:03, HLA-B*15:07, 
HLA-B*15:11, HLA-B*35:01, 
HLA-B*35:05, HLA-B*40:01, 
HLA-B*40:02, HLA-B*40:06, 
HLA-B*44:03, HLA-B*44:04, 
HLA-B*44:06, HLA-B*45:01, 
HLA-B*48:01, HLA-B*48:03, 
HLA-B*51:01, HLA-B*52:01, 
HLA-B*53:01, HLA-B*53:03 
36 
HLA-A*23:01, HLA-A*24:02, 
HLA-A*24:07, HLA-A*24:20, 
HLA-A*26:01, HLA-A*29:02, 
HLA-A*30:02, HLA-A*31:08, 
HLA-A*32:01, HLA-A*34:01, 
HLA-B*15:03, HLA-B*15:04, 
HLA-B*15:13, HLA-B*27:04, 
HLA-B*27:05, HLA-B*35:01, 
HLA-B*35:05, HLA-B*44:06, 
HLA-B*46:01, HLA-B*52:01, 
HLA-B*53:01, HLA-B*53:03, 
HLA-A*23:01, HLA-B*13:01, 
HLA-B*13:02, HLA-B*15:01, 
HLA-B*15:07, HLA-B*15:11, 
HLA-B*40:01, HLA-B*40:02, 
HLA-B*40:06, HLA-B*44:03, 
HLA-B*44:04, HLA-B*48:01, 
HLA-B*48:03, HLA-B*51:01 
1 DRB1*01:02 1 DRB1*01:02 
Rv0996 
Q303E 
6 
HLA-A*30:01, HLA-A*31:01, 
HLA-A*74:01, HLA-B*15:03, 
HLA-B*27:04, HLA-B*27:05 
3 
HLA-A*31:01, HLA-B*27:04, 
HLA-B*27:05 
29 
DRB1*01:01, DRB1*01:02, 
DRB1*03:01, DRB1*03:02, 
DRB1*07:01, DRB1*08:01, 
DRB1*08:02, DRB1*08:03, 
DRB1*08:04, DRB1*08:07, 
DRB1*11:01, DRB1*11:02, 
DRB1*11:03, DRB1*11:04, 
29 
DRB1*01:01, DRB1*01:02, 
DRB1*03:01, DRB1*03:02, 
DRB1*07:01, DRB1*08:01, 
DRB1*08:02, DRB1*08:03, 
DRB1*08:04, DRB1*08:07, 
DRB1*11:01, DRB1*11:02, 
DRB1*11:03, DRB1*11:04, 
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DRB1*12:01, DRB1*12:02, 
DRB1*13:01, DRB1*13:03, 
DRB1*13:04, DRB1*14:01, 
DRB1*14:02, DRB1*14:03, 
DRB1*14:04, DRB1*14:05, 
DRB1*14:13, DRB1*15:01, 
DRB1*15:03, DRB1*15:04, 
DRB1*16:02 
DRB1*12:01, DRB1*12:02, 
DRB1*13:01, DRB1*13:03, 
DRB1*13:04, DRB1*14:01, 
DRB1*14:02, DRB1*14:03, 
DRB1*14:04, DRB1*14:05, 
DRB1*14:13, DRB1*15:01, 
DRB1*15:03, DRB1*15:04, 
DRB1*16:02 
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Regional population coverage for peptides encompassing residues under diversifying selection 
Supplementary Table 4. Predicted population coverage in 15 geographic regions for peptides encompassing wild-type and variant amino acid residues under diversifying selection.  
 Amino acid substitution under diversifying selection 
 AccD2 R233L Rv0987 V169L Rv0988 L191A 
 Variant MTBC strains HLA class II Variant MTBC strains HLA class II Variant MTBC strains HLA class II 
Region Lineage 
Frequency 
(%) 
Wild-type 
population 
coverage (%) 
Variant 
population 
coverage (%) 
Lineage 
Frequency 
(%) 
Wild-type 
population 
coverage (%) 
Variant 
population 
coverage (%) 
Lineage 
Frequency 
(%) 
Wild-type 
population 
coverage (%) 
Variant 
population 
coverage (%) 
North America 1 8.40 17.32 22.93 1 and 2 26.89 36.67 45.20 2 18.49 45.20 36.67 
Central America 1 0.00 3.44 4.19 1 and 2 0.00 15.88 19.01 2 0.00 19.01 15.88 
West Indies 1 0.00 14.95 22.26 1 and 2 3.17 38.43 44.62 2 3.17 44.62 38.43 
South America 1 0.00 6.81 11.13 1 and 2 0.00 19.33 23.38 2 0.00 23.38 19.33 
Europe 1 6.43 17.14 21.24 1 and 2 15.66 41.30 50.00 2 9.29 50.00 41.30 
North Africa 1 2.43 11.00 12.92 1 and 2 7.90 40.32 45.05 2 5.47 45.05 40.32 
West Africa 1 1.85 10.73 13.06 1 and 2 4.55 43.43 47.09 2 2.70 47.09 43.43 
Central Africa 1 0.00 11.64 19.17 1 and 2 0.00 32.30 39.79 2 0.00 39.79 32.30 
East Africa 1 9.93 15.54 26.04 1 and 2 14.37 25.35 36.32 2 4.44 36.32 25.35 
South Africa 1 0.00 0.00 0.00 1 and 2 22.53 0.00 0.00 2 22.53 0.00 0.00 
Southwest Asia 1 7.75 6.64 7.85 1 and 2 18.98 20.64 30.45 2 11.23 30.45 20.64 
South Asia 1 31.74 9.25 15.41 1 and 2 44.94 40.14 46.14 2 13.20 46.14 40.14 
Eastern Asia 1 6.32 6.71 24.60 1 and 2 71.29 15.07 33.15 2 64.97 33.15 15.07 
Southeast Asia 1 42.76 0.78 30.62 1 and 2 88.31 10.12 38.84 2 45.55 38.84 10.12 
Oceania 1 22.30 0.81 15.68 1 and 2 39.72 2.67 18.36 2 17.42 18.36 2.67 
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In vitro HLA-binding assays 
 
Supplementary Table 5. Purity of synthesized peptides for the HLA-binding in vitro assays. 
Peptide Type Peptide sequence Purity (%) 
ESAT-63-17 Positive control EQQWNFAGIEAAASA 84.81 
AccD2228-241 Wild-type AEMHARISGLADYF 83.35 
AccD2228-241 Variant AEMHALISGLADYF 90.11 
Rv0987164-177 Wild-type RIALQVKGAPTTVT 81.27 
Rv0987164-177 Variant RIALQLKGAPTTVT 93.62 
Rv0988185-202 Wild-type LTLTQTAPPILQGNAGLS 82.03 
Rv0988185-202 Variant LTLTQTLPPILQGNAGLS 84.11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
